Chapter 3
TreatmentA | Overview of Treatment
CQ 3A-1

How should interventions and support be given following a diagnosis
of dementia?
AnswerTo improve the quality of life (QOL) of people with dementia and their families, it is necessary to provide postdiagnostic support from the early stage after dementia is diagnosed, which involves giving advice on ways to live withdementia, guidance to connect to social resources, and help with making future plans. Different countries adopt various
approaches of post-diagnostic support, including education on dementia and participation in peer support groups such as
dementia café, with some countries even considering to prepare written informed decision and future care plan according
to each person’s wishes. Careful discussions are required to find the approaches of post-diagnostic interventions andsupport which are appropriate to Japan.

Comment and evidence
Until now, medical care for dementia has focused on early diagnosis and treatment initiation. However, it has been
pointed out that these approaches alone are not sufficient to mitigate the psychological impact on the patients and theirfamilies or their fear of a future without hope. The current view is that to help persons affected by dementia prepare their
future with confidence, post-diagnostic support is necessary from the early stage following the diagnosis, by providing usefuladvice on living with dementia and information on social resources, and helping them plan the future. Such approaches havealready been started in some countries 1).
Regarding the future approaches of post-diagnostic intervention and support in Japan, careful discussions from various
perspectives are needed, taking into consideration the unique cultural characteristics and actual circumstances in Japan.

▪ References
1) Innes A, Szymczynska P, Stark C. Dementia diagnosis and post-diagnostic support in Scottish rural communities: experiences of people withdementia and their families. Dementia (London). 2014; 13(2): 233-247.

▪ Search formula
PubMed search: July 7, 2015 (Tuesday)#1 “Dementia/therapy” [Majr] OR “Cognition Disorders/therapy” [Majr] OR “Memory Disorders/therapy” [Majr] OR ((dementia [TI] OR
cognition disorder* [TI] OR cognitive disorder* [TI] OR memory disorder* [TI]) AND (therapy [TI] OR therapeutic [TI] OR treatment [TI]))
OR(“Dementia/diagnosis” [Mesh] OR (dementia [TI] AND post [TI] AND (diagnosis [TI] OR diagnostic [TI] OR diagnoses [TI]))) AND(“Social Support” [Majr] OR support* [TI]) OR ((“Dementia” [Mesh] OR dementia [TI]) AND post-diagnostic) OR post-diagnostic support*
Ichushi search: July 7, 2015 (Tuesday)#1 (Dementia/MTH OR Dementia/TI OR Cognitive impairment/MTH OR Cognitive impairment/TI OR Cognitive function impairment /TI
OR Memory disorder/MTH OR Memory disorder/TI) AND ((SH = Therapeutic use, treatment, drug treatment, surgical treatment, transplantation,
dietary treatment, psychiatric treatment, radiologic treatment) OR Treatment/MTH OR Therapeutic use/MTH OR Treatment/TI OR Therapy/
TI)

34

Clinical Practice Guideline for Dementia 2017

CQ 3A-2

How should pharmacotherapy, non-pharmacologic interventions and care beprovided during treatment of dementia?
AnswerUse a combination of pharmacotherapy and non-pharmacologic interventions to treat dementia with the goal to
improve cognitive function and quality of life (QOL). For behavioral and psychological symptoms of dementia (BPSD),
in principle, non-pharmacologic interventions should take priority over pharmacotherapy. When using psychotropic
drugs, continuously monitor for adverse events and whether medication is necessary.

Comment and evidence
In the treatment of dementia, the target symptoms include cognitive impairment, which is called the core symptom, as
well as BPSD including delusion and irritability. Treat these symptoms by a combination of pharmacotherapy and nonpharmacologic interventions. When BPSD are observed, investigate whether there are physical diseases causing these
symptoms and whether care is appropriate; and for treatment, give priority to non-pharmacologic interventions overpharmacotherapy 1, 2).

1. Treatment for cognitive impairment
For Alzheimer’s disease dementia, cholinesterase inhibitors and NMDA receptor antagonist are recommended.
Cholinesterase inhibitors are recommended for dementia with Lewy bodies. After medication is started, evaluate cognitive
function regularly by psychological tests such as the Mini-Mental State Examination.

2. Treatment for BPSD
For BPSD, evaluate changes in physical conditions that may have caused the symptoms, and whether care and environment
are appropriate 1). For environmental modification, consider using long-term care insurance services such as day service.
Non-pharmacologic interventions mitigate BPSD 3). Care for patients with dementia, whether at home or in an institution,
should be based on person-centered care that respects the will and hope of individual patients 4). Giving guidance to caregivers
regarding appropriate care delays admission to institution 5). Occupational therapy using sensory stimulation is reported to
improve BPSD 6).
After starting psychotropic drugs, continuously evaluate efficacy and adverse effects. If the demerits outweigh the benefits,consider dose reduction or discontinuation of the drug, while paying attention to the possibility of relapse of psychiatric
symptoms following drug withdrawal 1).

▪ References
1) Kales HC, Gitlin LN, Lyketsos CG, et al. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from amultidisciplinary expert panel. J Am Geriatr Soc. 2014; 62(4): 762-769.
2) Gauthier S, Cummings J, Ballard C, et al. Management of behavioral problems in Alzheimer’s disease. Int Psychogeriatr. 2010; 22(3): 346-372.
3) Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;
169(9): 946-953.
4) Kitwood T (translated by Takahashi S). Person-centered Care for Dementia. Tokyo: Tsutsui Shobo; 2005: 5-37. (In Japanese)5) Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of e­fficacy. Dement Geriatr Cogn
Disord. 2010; 30(2): 161-178.
6) Kim SY, Yoo EY, Jung MY, et al. A systematic review of the effects of occupational therapy for persons with dementia: a meta-analysis of randomized
controlled trials. NeuroRehabilitation. 2012; 31(2): 107-115.

▪ Search formula
PubMed search: July 7, 2015 (Tuesday)#1 ((“Dementia/drug therapy” [Majr] OR (dementia [TI] AND (“drug therapy” [TI] OR chemotherapy [TI] OR pharmacotherapy [TI] OR“pharmacological therapy” [TI]))) OR (“Cognition Disorders/drug therapy” [Majr] OR ((cognition disorder* [TI] OR cognitive disorder* [TI])
AND (“drug therapy” [TI] OR chemotherapy [TI] OR pharmacotherapy [TI] OR “pharmacological therapy” [TI]))) OR (“Memory Disorders/drug therapy” [Majr] OR (memory disorder* [TI] AND (“drug therapy” [TI] OR chemotherapy [TI] OR pharmacotherapy [TI] OR

Chapter 335

“pharmacological therapy” [TI])))) OR ((“Dementia/rehabilitation” [Majr] OR (dementia [TI] AND rehabilitation [TI]))OR(“Cognition Disorders/rehabilitation” [Majr]OR((cognition disorder* [TI]OR cognitive disorder* [TI]) AND rehabilitation [TI])) OR (“Memory Disorders/rehabilitation”[Majr] OR (memory disorder* [TI] AND rehabilitation [TI]))) OR ((“Dementia/therapy” [Majr] AND “Rehabilitation” [Mesh]) OR (“Cognition
Disorders/therapy” [Majr] AND “Rehabilitation” [Mesh]) OR (“Memory Disorders/therapy” [Majr] AND “Rehabilitation” [Mesh])) OR((“Dementia/nursing” [Majr] OR (dementia [TI] AND nursing [TI])) OR (“Cognition Disorders/nursing” [Majr] OR ((cognition disorder* [TI]
OR cognitive disorder* [TI]) AND nursing [TI])) OR (“Memory Disorders/nursing” [Majr] OR (memory disorder* [TI] AND nursing [TI])) OR((“Dementia/diet therapy” [Majr] OR (dementia[TI] AND “diet therapy” [TI])) OR (“Cognition Disorders/diet therapy” [Majr] OR ((cognition
disorder* [TI] OR cognitive disorder* [TI]) AND “diet therapy” [TI])) OR (“Memory Disorders/diet therapy” [Majr] OR (memory disorder* [TI]
AND “diet therapy”[TI]))) OR (( “Dementia/surgery” [Majr] OR (dementia[TI] AND (surg* [TI] OR operation* [TI]))) OR (“Cognition Disorders/surgery” [Majr] OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND (surg*[TI] OR operation* [TI]))) OR (“Memory Disorders/surgery” [Majr] OR (memory disorder* [TI] AND (surg* [TI] OR operation* [TI])))) OR ((“Dementia/radiotherapy” [Majr] OR (dementia [TI]
AND radiotherapy [TI])) OR (“Cognition Disorders/radiotherapy” [Majr] OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND
radiotherapy [TI])) OR (“Memory Disorders/radiotherapy” [Majr] OR (memory disorder* [TI] AND radiotherapy [TI]))) OR (((“Dementia/
therapy” [Majr] AND “Psychotherapy” [Mesh]) OR (dementia [TI] AND psychotherapy [TI])) OR (“Cognition Disorders/therapy” [Majr] AND“Psychotherapy” [Mesh]) OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND psychotherapy [TI]) OR (“Memory Disorders/therapy”[Majr] AND “Psychotherapy” [Mesh]) OR (memory disorder* [TI] AND psychotherapy [TI])) OR (((“Dementia/therapy” [Majr] AND “Social
Support” [Mesh]) OR (dementia [TI] AND social support* [TI])) OR (“Cognition Disorders/therapy” [Majr] AND “Social Support” [Mesh]) OR((cognition disorder* [TI] OR cognitive disorder* [TI]) AND social support* [TI]) OR (“Memory Disorders/therapy” [Majr] AND “Social
Support” [Mesh]) OR (memory disorder* [TI] AND social support* [TI])) OR ((“Dementia/therapy” [Majr] AND “Patient Care” [Mesh]) OR(dementia [TI] AND “patient care” [TI])) OR (“Cognition Disorders/therapy” [Majr] AND “Patient Care” [Mesh]) OR ((cognition disorder* [TI]
OR cognitive disorder* [TI]) AND “patient care” [TI]) OR (“Memory Disorders/therapy” [Majr] AND “Patient Care” [Mesh]) OR (memory
disorder* [TI] AND “patient care” [TI]) OR ((“Dementia/therapy”[Majr] AND “Quality of Life” [Mesh]) OR (dementia [TI] AND quality of life*[TI])) OR (“Cognition Disorders/therapy” [Majr] AND “Quality of Life” [Mesh]) OR ((cognition disorder* [TI] OR cognitive disorder* [TI])
AND quality of life* [TI]) OR (“Memory Disorders/therapy” [Majr] AND “Quality of Life” [Mesh]) OR (memory disorder* [TI] AND quality oflife* [TI]) OR ((“Dementia/therapy” [Majr] AND “Informed Consent” [Mesh]) OR (dementia [TI] AND “informed consent” [TI]) OR (“Cognition
Disorders/therapy” [Majr] AND “Informed Consent” [Mesh]) OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND “informed
consent” [TI]) OR (“Memory Disorders/therapy” [Majr] AND “Informed Consent” [Mesh]) OR (memory disorder* [TI] AND “informed consent”[TI]) OR ((“nonpharmacological therapy” OR “non pharmacological therapy”) AND (“Dementia/therapy” [Majr] OR dementia [TI] OR“Cognition Disorders/therapy” [Majr] OR cognition disorder* [TI] OR cognitive disorder* [TI] OR “Memory Disorders/therapy” [Majr] OR
memory disorder* [TI]))
Ichushi search: July 7, 2015 (Tuesday)#1 (Dementia/MTH OR Dementia/TI OR Cognitive impairment/MTH OR Cognitive impairment/TI OR Cognitive function impairment/TI
OR Memory disorder/MTH OR Memory Disorder/TI) AND ((SH = Pharmacotherapy, Rehabilitation, Nursing, Surgical therapy, Transplantation,
Dietary therapy, Psychiatric therapy, Radiotherapy) OR Pharmacotherapy/MTH OR Pharmacological action/MTH OR Pharmacotherapy/TI OR
Pharmacotherapy/TI OR Medication/TI OR Rehabilitation/MTH OR Rehabilitation/TI OR Nursing/MTH OR Nursing/TI OR Surgery/MTH
OR Surgical operation/TI OR Surgery/TI OR Transplantation/TI OR Dietary therapy/MTH OR Dietary therapy/TI OR Therapeutic diet/TI OR
Psychiatric therapy/TH OR Psychiatric therapy/TI OR Radiotherapy/MTH OR Radiological treatment/TI OR Radiotherapy/TI OR Social
support/MTH OR Social support/TI OR Patient management/MTH OR Patient management/TI OR Patient care/TI OR Informed consent/TH
OR “Informed Consent”/TI OR QOL/TH OR QOL/TI OR “Quality of Life”/TI)

36

Clinical Practice Guideline for Dementia 2017

CQ 3A-3

What are the principles and precautions of pharmacotherapy in older people
with dementia?
AnswerOlder people with dementia tend to develop adverse events during pharmacotherapy. (1) Consider starting with a low
dose, such as one-half to one-quarter of the dose used in young adults, depending on the type of drug to be prescribed.
(2) Evaluate drug efficacy after a short period of treatment. (3) Simplify the method of drug taking. (4) Avoid taking
multiple drugs as far as possible, while paying attention to adverse events specific to older people. Periodically evaluate thetype of drug, the dosage, and the necessity of long-term prescription. (5) Confirm adherence to drug-taking with family
members, caregivers, pharmacists, and others.

Comments and evidence
Many older people are affected by multiple diseases and the symptoms tend to be atypical. In addition, they show large
individual differences in symptoms and response to drugs. For these reasons, they tend to use multiple drugs in combination
for prolonged periods. The frequencies of adverse events are also high in older people; 15% of those aged 75 years or above
have adverse events 1).
In view of the physiological deterioration of liver and renal functions in older people, consider starting with a low dose,such as one-half to one-quarter of the dose used in young adults, depending on the type of drug used.
Evaluate efficacy after a short period of treatment.
Simplify the method of drug taking.
Avoid using multiple drugs.
Confirm adherence to drug-taking with both the patient and also the caregiver.

▪ References
1) Toba K, Akishita M, Mizuno Y, et al. Adverse drug reaction in the elderly. Japanese Journal of Geriatrics (Nippon Ronen Igakkai Zasshi) 1999;
36(3): 181-185. (In Japanese)▪ Search formula
PubMed search: July 7, 2015 (Tuesday)#1 (“Dementia/drug therapy” [Majr] OR (dementia [TI] AND (“drug therapy” OR chemotherapy)) OR “Cognition Disorders/drug therapy” [Majr]
OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND (“drug therapy” OR chemotherapy)) OR “Memory Disorders/drug therapy”[Majr] OR(memory disorder* [TI] AND (“drug therapy” OR chemotherapy))) AND “Aged, 80 and over” [Mesh]
Ichushi search: July 6, 2015 (Monday)#1 (Dementia/MTH OR Dementia/TI OR Cognitive impairment/MTH OR Cognitive impairment/TI OR Cognitive function impairment/TI
OR Memory disorder/MTH OR Memory disorder/TI) AND (CK = Elderly (80~)) AND ((SH = Pharmacotherapy) OR Pharmacotherapy/MTH
OR Pharmacological effect/MTH OR Drug treatment/TI OR Pharmacotherapy /TI OR Therapeutic drug/TI)

Chapter 3

37

CQ 3A-4

What are the adverse events of psychotropic drugs [such as falls, declined activityof daily living (ADL), cognitive impairment, and aspiration pneumonia]?
AnswerAdverse events of antipsychotic drugs include over-sedation, hypotension, falls, dysphagia, constipation, and neuroleptic
malignant syndrome. Antipsychotic drugs are also associated with increased risk of death. Pay special attention to impaired
glucose tolerance when using olanzapine and quetiapine. Selective serotonin reuptake inhibitor (SSRI) and serotoninnorepinephrine reuptake inhibitor (SNRI) may cause nausea, loose stools, and serotonin syndrome. Benzodiazepine
anxiolytics and hypnotic drugs may cause falls, aspiration, somnolence, and respiratory depression.
A

Comments and evidence
Older people with dementia are prescribed drugs under the situations of impaired walking function and judgement ability
together with increased susceptibility to developing adverse events. Adverse events of antipsychotics include over-sedation,
falls, fracture, dysphagia, constipation, urinary tract infection, cerebrovascular disease, cardiovascular event, venous
thrombosis, edema, gait disturbance, neuroleptic malignant syndrome, and increased risk of death 1).
Olanzapine and quetiapine are contraindicated in patients with diabetes and those with a history of diabetes. Risperidone
and aripiprazole should be administered with caution in patients with diabetes or a history of diabetes, and patients with risk
factors of diabetes including a family history of diabetes, hyperglycemia, and obesity. For olanzapine, quetiapine, andaripiprazole, warning has been issued regarding the need to monitor blood glucose and explain to patients what to do whenadverse effects occur.
The antidepressant SSRI and SNRI may cause gastrointestinal symptoms such as nausea and loose stools, and serotonin
syndrome (including tremor, sweating, tachycardia, anxiety, and agitation). Among anxiolytics and hypnotic drugs,
benzodiazepines is the main drug class that may cause weakness, falls, aspiration, dysphagia, somnolence, and respiratory
depression, etc.

▪ Reference
1) Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs:
population based cohort study. BMJ. 2012; 344: e977.

▪ Search formula
PubMed search: July 7, 2015 (Tuesday)#1 (“Dementia/drug therapy” [Mesh] OR (dementia [TI] AND (“drug therapy” OR chemotherapy)) OR “Cognition Disorders/drug therapy”[Mesh] OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND (“drug therapy” OR chemotherapy)) OR “Memory Disorders/drug
therapy” [Mesh] OR (memory disorder* [TI] AND (“drug therapy” OR chemotherapy))) AND (“Psychotropic Drugs/adverse effects” [Mesh] OR((psychotropic drug* [TI] OR psychotropic agent* [TI]) AND (side effect* [TI] OR adverse effect* [TI] OR adverse reaction* [TI])) OR“Psychopharmacology/adverse effects” [Mesh] OR (psychopharmacology [TI] AND (side effect* [TI] OR adverse effect* [TI] OR adverse reaction*[TI])) OR ((antipsychotic agent* [TI] OR antipsychotic drug* [TI]) AND (side effects* [TI] OR adverse effect* [TI] OR adverse reaction* [TI])))
Ichushi search: July 6, 2015 (Monday)#1 (Dementia/MTH OR Dementia/TI OR Cognitive impairment/MTH OR Cognitive impairment/TI OR Cognitive function impairment/TI
OR Memory disorder/MTH OR Memory disorder/TI) AND ((SH = Pharmacotherapy) OR Pharmacotherapy /MTH OR Pharmacological action/
MTH OR Drug treatment/TI OR Pharmacotherapy/TI OR Therapeutic drug/TI) AND (Antipsychotic drug/TH OR Antipsychotic drug/TI OR
Psychopharmacology/TH OR Psychopharmacology/TI OR Antipsychotic drug/TI)AND ((SH = Toxicity·Adverse effect, Chemical induction,
Adverse effect) OR Toxicity/TI OR Side effect/TI OR Adverse/TI)

38

Clinical Practice Guideline for Dementia 2017

CQ 3A-5

What are the treatment procedures when using pharmacotherapy for dementia?
Answer
Before starting pharmacotherapy for dementia patients, consider carefully whether such therapy is necessary. Ifpharmacotherapy is required, confirm adherence to drug taking and the indications of the drug, give sufficient explanations
to patients and caregivers, and then start treatment.
B

Comments and evidence
Since older people already have other physical illnesses, they may be using a combination of multiple drugs. Before
starting pharmacotherapy for dementia, consider carefully the necessity of the therapy, and initiate treatment if the treatment
is judged to be necessary.
Before initiating pharmacotherapy, explain the general benefits and risks of pharmacotherapy using language that is easy
to understand even for the patient with dementia, and give due consideration also to respect the will of the patient. Despite
these explanations, if the patient’s intention cannot be confirmed, or if the patient lacks the ability to make a judgment,
explain to family members or other proxies and obtain consent.
People with dementia have difficulties managing medication from a relatively early stage of the disease due to cognitive
impairment. Accidents such as unintentional overdose may occur due to the inability to manage medication. Whenprescribing medications for patients with dementia, it is necessary to simplify the method of drug taking such as minimizing
the number of drug-taking, to facilitate visual medication management by dispensing drugs together in one package or using
a pill box, and to modify the environment so that it can be shared between the patient and caregiver. Depending on theseverity of dementia, the caregiver may need to fully manage the medication. It is desirable to start pharmacotherapy after
making the above preparations and confirming that the environment allows maintenance of good adherence.
Behavioral and psychological symptoms of dementia (BPSD) can appear at any stage of dementia. Parallel topharmacotherapy for cognitive impairment, start treatment (non-pharmacological interventions or pharmacotherapy) for
BPSD any time when the need arises. Also provide concomitant treatments for neurological symptoms associated with theprimary disease, coexisting conditions specific to older people (including delirium, dysphagia, falls/fractures, pneumonia,
urinary disorder, and constipation), and physical complications (including hypertension, diabetes, and dyslipidemia).
Regardless of the drugs used, pay close attention to adverse events. When adverse events are observed, consider changing
or discontinuing the drug promptly.

▪ Further reading
1) Toba K. Dementia (second volume): Pharmacotherapy for dementia: compliance and adherence to drug taking. Japanese Journal of Clinical
Medicine (Nihon Rinsho) 2011; 69: 22-25 (In Japanese)
2) Japan Geriatrics Society, Japan Agency for Medical Research and Development / Study Group on Safety of Medical Treatment in the Elderly (Ed.)
Guidelines for Medical Treatment and its Safety in the Elderly 2015. Tokyo; Medical Tribune; 2015. (In Japanese)▪ Search formula
PubMed search: July 4, 2015 (Saturday), July 18, 2015 (Saturday)#1 “Dementia/drug therapy” [Majr] OR (dementia[TI] AND (“drug therapy” OR chemotherapy)) OR “Cognition Disorders/drug therapy” [Majr]
OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND(“drug therapy” OR chemotherapy)) OR “Memory Disorders/drug therapy”[Majr] OR (memory disorder* [TI] AND (“drug therapy” OR chemotherapy))
Ichushi search: July 4, 2015 (Saturday)#1 (Dementia/MTH OR Dementia/TI OR Cognitive impairment/MTH OR Cognitive impairment/TI OR Cognitive function impairment/TI
OR Memory disorder/TI OR Memory disorder/TI) AND ((SH = Pharmacotherapy) OR Pharmacotherapy/MTH OR Pharmacological action/
MTH OR Drug treatment/TI OR Pharmacotherapy/TI OR Therapeutic drug/TI)

Chapter 3

39

CQ 3A-6

What are the adverse events due to cholinesterase inhibitors and NMDA
receptor antagonists, and what should be done in case of these events?
Recommendation
The common adverse events of cholinesterase inhibitors are gastrointestinal symptoms including nausea/vomiting anddiarrhea.
The common side effects of NMDA receptor antagonists include somnolence, dizziness, constipation, and headache.
In principle, these adverse events are managed by dose reduction or discontinuation of the responsible drug.

1B

Comments and evidence
Regarding serious adverse events of medications used to treat Alzheimer’s disease dementia, cholinesterase inhibitors havebeen reported to cause adverse effects of the cardiovascular system such as syncope, bradycardia, and QT prolongation 1). The
NMDA receptor antagonist memantine has been reported to cause serious adverse events including syncope and psychiatric
symptoms 2).
Cholinesterase inhibitors are associated with high frequencies of adverse events of the gastrointestinal system such as
diarrhea, nausea/vomiting, and headache 3). Gastrointestinal symptoms are more likely to appear when administration is
initiated or when the dose is increased, and the incidence increases as the dose becomes higher. The rates of syncope 1, 4),
fracture 1, 4), accidental injury 4), bradycardia 1), pacemaker implantation 1) have been shown to be higher under administrationof cholinesterase inhibitors compared to controls 3). Rivastigmine patch is a transdermal formulation that achieves relatively
stable blood level. While the frequency of gastrointestinal symptoms associated with the patch formulation is lower than thatof the oral formulation 5), skin reaction may occur at the site of application.
Although dizziness, somnolence, headache, and constipation have been reported to be relatively frequent adverse effectsof memantine 2), one meta-analysis finds no significant difference compared with placebo 6).
Since the frequencies of occurrence of common adverse events differ depending on the disease, attention is required.
There is little evidence on how to manage adverse effects. Domperidone may be effective for gastrointestinal symptoms 7).
A moisturizer may be used to prevent inflammation at the site of application of the rivastigmine patch. If inflammation
persists, consider using topical steroids 8).
In all cases, including those mentioned above, if adverse events are serious, consider reducing the dose or discontinuing
the causative drug.
There is little evidence on the treatment of acute intoxication due to overdose or mistaken administration. Since acuteintoxication may sometimes lead to death, caution is required.

▪ References
1) Howes LG. Cardiovascular e­ffects of drugs used to treat Alzheimer’s disease. Drug Saf. 2014; 37(6): 391-395.
2) Honma A, Ozawa M, Shiosakai K, et al. Safety and efficacy of memantine hydrochloride in patients with Alzheimer’s disease: Interim results ofspecified drug use survey on long-term use of memantine hydrochloride. Journal of Geriatrics(Nippon Ronen Igakkai Zasshi) 2014; 25(4): 419-433.
(In Japanese)3) Ihl R, Frolich L, Winblad B, et al. WFSBP Task Force on Treatment Guidelines for Alzheimer’s Disease and other Dementias. World Federation ofSocieties of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer’s disease and other dementias. World J Biol
Psychiatry. 2011; 12(1): 2-32.
4) Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis ofrandomized controlled trials. J Am Geriatr Soc. 2011; 59(6): 1019-1031.
5) Birks JS, Grimley Evans J. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev. 2015; (4): CD001191.
6) Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer’s disease: a systematic review and meta-analysis. PLoS One. 2015; 10(4):e0123289.
7) Kano O, Urita Y, Ito H, et al. Domperidone e­ffective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s
disease. Neuropsychiatr Dis Treat. 2013; 9: 1411-1415.
8) Tahira T. Pharmacotherapy‒core symptom. Tahira T: ABC of New Diagnosis and Treatment 22; Neurology 3; Alzheimer’s Disease Dementia 2nd
Edition. 138-145, Osaka: Saishin Igakusha; 2014. (In Japanese)

40

Clinical Practice Guideline for Dementia 2017

▪ Search formula
PubMed search: July 4, 2015 (Saturday)#1 (“Dementia/drug therapy” [Mesh] OR (dementia [TI] AND (“drug therapy” OR chemotherapy)) OR “Cognition Disorders/drug therapy”[Mesh] OR ((cognition disorder* [TI] OR cognitive disorder* [TI]) AND (“drug therapy” OR chemotherapy)) OR “Memory Disorders/drug
therapy” [Mesh] OR (memory disorder* [TI] AND (“drug therapy” OR chemotherapy))) AND (“Cholinesterase Inhibitors/adverse effects” [Mesh]
OR (cholinesterase inhibitor* [TI]) OR “Memantine/adverse effects” [Mesh] OR (memantine [TI] OR NMDA receptor antagonist* [TI] OR
N-Methyl-D-Aspartate receptor antagonist* [TI]))
Ichushi search: July 4, 2015 (Saturday)#1 (Dementia/TH OR Dementia/TI OR Cognitive impairment/TH OR Cognitive impairment/TI OR Cognitive function impairment/TI OR
Cognitive impairment/TH OR Memory disorder/TI) AND (((“Cholinesterase Inhibitors”/TH OR “Cholinesterase Inhibitor”/TI OR cholinesterase
inhibitor/TI OR cholinesterase inhibitor/TI)AND((SH = Toxicity/side effect, chemical induction, adverse effect) OR adverse reaction/TI OR
adverse effect/TI OR toxicity/TI)) OR ((Memantine/TH OR Memantine/TI OR memantine/TI OR NMDA receptor antagonist/TI OR NMDA
receptor antagonist/TI) AND ((SH = side effect, chemical induction, adverse effect) OR adverse reaction/TI OR adverse effect/TI OR toxicity/TI)))

Chapter 3

41

CQ 3A-7-1

What are the non-pharmacological therapies for dementia?
AnswerNon-pharmacological interventions for persons with dementia include cognitive function training, cognitive
stimulation, exercise therapy, reminiscence, music therapy, and activities of daily living (ADL) training.
C

Comment and evidence
Among the treatments for dementia, all the therapies other than pharmacotherapy are grouped together as nonpharmacological therapies. Non-pharmacological therapies aim to improve not only cognitive impairment but also behavioral
and psychological symptoms of dementia (BPSD) as well as functions of daily living. Non-pharmacological therapies fordementia are broadly divided into interventions for patients with dementia and interventions for the caregivers. In practice,
however, the two kinds of interventions are conducted in combination.
It should be noted that non-pharmacological therapies are intended not only for mitigating psychiatric symptoms andbehavioral disorders but also for other benefits. For example, methods such as music therapy and reminiscence therapy arehighly significant as means to engage dementia patients in active communication and involve them in daily living. Therefore,
the validity and importance of these therapies cannot be judged solely based on whether mental symptoms are improved. In
the clinical setting, it is necessary to consider intervention methods also for the purpose of maintaining the patients’ qualityof life (QOL) and their motivation in daily living.
Caregivers also should receive care. Appropriate interventions for caregivers are effective to preventive burnout. Structured
psychological education for caregivers (a combination of learning knowledge, communication skills, behavior management,
cognitive behavioral therapy, etc.) has been shown to reduce caregiver burnout and depression 1).

▪ Reference
1) Jensen M, Agbata IN, Canavan M, et al. E­ffectiveness of educational interventions for informal caregivers of individuals with dementia residing in
the community: systematic review and meta-analysis of randomised controlled trials. Int J Geriatr Psychiatry. 2015; 30 (2):130-143.

▪ Further reading
1) Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn
Disord. 2010; 30(2): 161-178.
2) Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;
169(9): 946-953.

▪ Search formula
PubMed search: July 4, 2015 (Saturday), August 3, 2015 (Sunday)#1 (“Dementia/therapy” [Majr] OR (dementia [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Cognition Disorders/therapy” [Majr] OR (“cognition disorder*” [TI] AND (therapy [TI] OR therapeutic[TI] OR treatment [TI])) OR “Memory Disorders/therapy”[Majr] OR (memory disorder* [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI]))) NOT (“Dementia/drug therapy” [Mesh] OR(dementia [TI] AND (“drug therapy” OR chemotherapy)) OR “Cognition Disorders/drug therapy” [Mesh] OR (“cognition disorder*” [TI] AND(“drug therapy” OR chemotherapy)) OR “Memory Disorders/drug therapy” [Mesh] OR (memory disorder* [TI] AND (“drug therapy” ORchemotherapy))) OR (“Dementia/therapy” [Mesh] OR (dementia [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Cognition
Disorders/therapy” [Mesh] OR (“cognition disorder*” [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Memory Disorders/therapy” [Mesh] OR (memory disorder* [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI]))) AND (neuropsychiatric symptom* OR
behavioral symptom* OR behavioural symptom* OR psychological symptom*) OR “neuropsychiatric symptoms of dementia” OR “behavioral andpsychological symptoms of dementia”
Ichushi search: July 4, 2015 (Saturday)#1 (Dementia/TH OR Dementia/TI OR Cognitive impairment/TH OR Cognitive impairment/TI OR Cognitive function impairment/TI OR
Memory disorder/TI OR Memory disorder/TI ) AND ((SH = Therapeutic use, treatment, drug treatment, surgical treatment, transplantation,
dietary treatment, psychiatric treatment, radiologic treatment)OR Treatment/TH OR Treatment/TI OR Therapy/TI) NOT ((SH = Pharmacotherapy)
OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/TI OR Therapeutic drug/TI)

42

Clinical Practice Guideline for Dementia 2017

CQ 3A-7-2

What are the symptoms that respond to non-pharmacological therapies fordementia?
Recommendation
Non-pharmacological therapies and exercise therapy that exert effects on cognitive function, such as cognitive
stimulation, are effective in improving cognitive impairment in dementia. Exercise therapy may be effective in improving
activities of daily living (ADL), and music therapy may be effective to treat behavioral and psychological symptoms ofdementia (BPSD).
2C

Comments and evidence
Non-pharmacological therapies that are effective for cognitive impairment in Alzheimer’s disease dementia include
cognitive stimulation 1, 2). A meta-analysis shows that interventions using cognitive stimulation improves the Mini Mental
State Examination score by 1.74 points (95% confidence interval 1.13 to 2.36) and ADAS-cog by 2.27 points (95%
confidence interval 0.99 to 3.55) compared to the no intervention group, and the effect remains evident during the follow-up
period of 1 to 3 months 3). Multi-component interventions have also been shown to improve ADL, quality of life (QOL), as
well as behavior and mood 1). When cognitive stimulation is used, participants’ self-evaluation for QOL and well-being
improves 1). However, little evidence is available for other non-pharmacological interventions including transcutaneouselectrical stimulation therapies (transcranial, peripheral), exercise therapy, music therapy, reminiscence therapy, ADL
training, massage, recreational therapy, light therapy, multisensory stimulation therapy, supportive psychotherapy, validation
therapy, acupuncture, transcranial magnetic stimulation, and muscle relaxation. Future reports with high-quality evidence
are awaited. In the actual clinical setting, it is important to select an intervention method that matches the individuality ofthe patient.
Providing multi-component interventions including psychological education for caregivers delays institutionalization ofhome-care patients, reduces BPSD, and improves caregiver outcomes.

▪ References
1) Olazaran J, Reisberg B, Clare L, et al. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of e­fficacy. Dement Geriatr Cogn
Disord. 2010; 30(2): 161-178.
2) Brodaty H, Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. Am J Psychiatry. 2012;
169(9): 946-953.
3) Woods B, Aguirre E, Spector AE, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst
Rev. 2012; 2: CD005562.

▪ Search formula
PubMed search: July 4, 2015 (Saturday), August 3, 2015 (Sunday)#1 (“Dementia/therapy” [Majr] OR (dementia [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Cognition Disorders/therapy” [Majr] OR (“cognition disorder*” [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Memory Disorders/therapy”[Majr] OR (memory disorder* [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI]))) NOT (“Dementia/drug therapy” [Mesh] OR(dementia [TI] AND (“drug therapy” OR chemotherapy)) OR “Cognition Disorders/drug therapy” [Mesh] OR (“cognition disorder*” [TI] AND(“drug therapy” OR chemotherapy)) OR “Memory Disorders/drug therapy” [Mesh] OR (memory disorder* [TI] AND (“drug therapy” ORchemotherapy))) OR (“Dementia/therapy” [Mesh] OR (dementia [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Cognition
Disorders/therapy” [Mesh] OR (“cognition disorder*” [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) OR “Memory Disorders/therapy” [Mesh] OR (memory disorder* [TI] AND (therapy [TI] OR therapeutic [TI] OR treatment [TI])) AND (neuropsychiatric symptom* OR
behavioral symptom* OR behavioural symptom* OR psychological symptom*) OR “neuropsychiatric symptoms of dementia” OR “behavioral andpsychological symptoms of dementia”
Ichushi search: July 4, 2015 (Saturday)#1 (Dementia/TH OR Dementia/TI OR Cognitive impairment/TH OR Cognitive impairment/TI OR Cognitive function impairment/TI OR
Memory disorder/TI OR Memory disorder/TI ) AND ((SH = Therapeutic use, treatment, drug treatment, surgical treatment, transplantation,
dietary treatment, psychiatric treatment, radiologic treatment) OR Treatment/TH OR Treatment /TI OR Therapy/TI) NOT ((SH =Pharmacotherapy) OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/TI OR Therapeutic drug/TI)

Chapter 3

43

B | Treatment for behavioral and psychological symptoms
of dementia (BPSD)
CQ 3B-1

What are the effective non-pharmacological therapies and pharmacotherapy
for anxiety?
Recommendation
Anxiety is an important symptom that can cause or induce other behavioral and psychological symptoms of dementia(BPSD). The fundamental approach is to interact with the patient by speaking in a reassuring tone with a caring attitude.
As non-pharmacological therapies for anxiety, music therapy and cognitive behavioral therapy may be effective, and theyshould be considered. If these treatments are not adequately effective, consider prescribing risperidone, olanzapine orquetiapine.
2C

Comments and evidence
Anxiety is an important symptom that can cause or induce other BPSD. First, the fundamental approach is to interact
with the patient in a reassuring voice and attitude. Music therapy has been confirmed to be effective as a non-pharmacologicaltherapy for anxiety 1). Music therapy is desirably provided directly by music therapists, and is especially recommended forpeople with moderate to severe dementia. Cognitive behavioral therapy has been shown to be effective for persons with mild
to moderate dementia 2).
If the above interventions do not provide adequate effect, consider pharmacotherapy.
A double-blind RCT comparing risperidone with haloperidol confirms the superiority of risperidone for anxiety symptoms 3).
Olanzapine has also been shown to be a safe and effective drug compared with placebo as control in a double-blind RCT for thetreatment of anxiety in patients with Alzheimer’s disease dementia 4). In an open-label study comparing quetiapine and haloperidol,
quetiapine improves anxiety and is well tolerated whereas haloperidol is not effective 5). Since these atypical antipsychotics are used
off-label, it is necessary to give adequate explanations to the patients and families, and to pay attention to adverse events while using
the drugs. In addition, even if a drug is effective, it should not be used casually; keep in mind to reduce the risk of adverse effects
by adjusting the dose or withdrawing the drug when symptoms have improved.
Benzodiazepines have been used to mitigate mild anxiety symptoms, but there is no clear evidence. When using this drug,
pay attention to adverse events such as sedation, disorientation, delirium, confusion, disinhibition, ataxia, falls, fracture, anddrug dependence at usual doses.

▪ References
References 3-5 on pharmacotherapy are the same as the references in the previous version of the guideline.
1) Raglio A, Bellelli G, Mazzola P, et al. Music, music therapy and dementia: a review of literature and the recommendations of the Italian Psychogeriatric
Association. Maturitas. 2012; 72(4): 305-310.
2) Stanley MA, Calleo J, Bush AL, et al. ­The Peaceful Mind Program: a pilot test of a CBT-based intervention for anxious patients with dementia. Am
J Geriatr Psychiatry. 2013; 21(7): 696-708.
3) Suh GH, Greenspan AJ, Choi SK. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Int J Geriatr Psychiatry. 2006; 21(7): 654-660.
4) Mintzer J, Faison W, Street JS, et al. Olanzapine in the treatment of anxiety symptoms due to Alzheimer’s disease: a post hoc analysis. Int J Geriatr
Psychiatry. 2001; 16(Suppl 1): S71-S77.
5) Savaskan E, Schnitzler C, Schroder C, et al. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer’s disease
haloperidol vs. quetiapine. Int J Neuropsychopharmacol. 2006; 9(5): 507-516.

▪ Search formulaNon-pharmacological therapy
PubMed search: October 2, 2015 (Friday)

44

Clinical Practice Guideline for Dementia 2017

#1 (“Dementia/therapy” [Majr] OR dementia [TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration” [TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [Mesh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indifference* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation [TI] OR “Irritable Mood” [Mesh] OR irritability [TI] OR“Delusions” [Mesh] OR delusion* [TI] OR “Hallucinations” [Mesh] OR hallucination* [TI] OR “Depression” [Mesh] OR depression [TI] OR
dysphoria [TI] OR “Wandering Behavior” [Mesh] OR wandering [TI] OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual
Behavior” [Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI] OR “inappropriate sexual behavior” [TI] OR restlessness[TI] OR(“Motor Activity” [Mesh]AND aberrant [TI]) OR “aberrant motor behaviour” [TI] OR “aberrant motor behavior” [TI] OR “Sleep
Disorders” [Mesh] OR “nighttime insomnia” [TI] OR “sleep disturbance” [TI] OR “daytime napping” [TI] OR “daytime sleepiness” [TI] OR“Apathy” [Mesh] OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indifference OR aggression OR agitation OR
irritability OR delusion* OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour”
OR “inappropriate sexual behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR“sleep disturbance” OR “daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR Alzheimer/TI OR frontotemporal lobar degeneration/TI OR “frontotemporal lobar
degeneration”/TI) AND ((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR Non-pharmacotherapy/
TI OR Non-pharmacological treatment/TI OR validation therapy/TH OR validation therapy/TI OR “validation therapy”/TI OR Reality
orientation/TH OR “Reality orientation”/TI OR Reminiscence/TH OR Reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH
OR Music therapy/TI OR “music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR
Aromatherapy/TI OR “aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise
therapy/TH OR Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR
Physical exercise/TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive
training/TI OR “cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR“stimulation therapy”/TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver/TH OR
Caregiver/TI) AND (Education/TI OR Intervention/TI)) OR (caregiver/TI) AND (“psycho-education”/TI OR intervention/TI)) OR Nursing careservice/TH OR Nursing care service/TI OR “dementia care service”/TI OR Day care/TH OR Day care/TI OR “adult day service”/TI OR “dementia
day service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND (Anxiety/TH OR Anxiety/TI OR Indifference/TI
OR Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual
perversion/TH OR ((Deviation OR Abnormality) AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleeping disturbance/
TI OR Dyssomnia/TI OR Insomnia/TI OR Sleepiness/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 (Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug th­erapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR “Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine, Kampo” [Mesh]
OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease” OR “alzheimer’s
disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine OR“selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”))
Ichushi search: June 23, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI) AND ((SH = Pharmacotherapy) OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/
TI OR Therapeutic drug/TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Anxiety/TH OR Anxiety/TI OR Indifference/TI)

Chapter 3

45

CQ 3B-2

What are the effective non-pharmacological therapies and pharmacotherapy
for agitation?
Recommendation
Treat agitation based on person-centered care; consider the reasons and causes for the symptoms and try to resolve
them. It is also effective for the caregivers to learn appropriate conversation skills with persons with dementia and topractice the skills. Other non-pharmacological interventions such as group activities, music therapy, tactile care, andmassage have been shown to be effective. For pharmacotherapy, atypical antipsychotics such as risperidone and aripiprazole
have been shown to be effective. Consider also to use Yokukansan (liver-inhibiting powder), tiapride, carbamazepine,
sertraline, escitalopram, and trazodone.
2C

Comments and evidence
In a systematic review that examines the effectiveness of 33 non-pharmacological interventions for agitation, educating
caregivers about personal-centered care and training them to acquire appropriate communication skills with persons withdementia improve agitation 1). Other non-pharmacological therapies including group activities, music therapy conducted byexperts based on a program, tactile care, and massage have been shown to be effective.
If non-pharmacological therapies do not provide adequate effect, consider pharmacotherapy. Note that all the drugs
described below are used off-label, and should be used with caution after explaining adequately to the patients and families
and paying attention to adverse events during use. In addition, even when a drug is effective, it should not be used casually,and efforts should be made to decrease the risk of adverse effects by reducing the dose or withdrawing the drug when
symptoms have improved.
In a systematic review that summarizes 18 studies on atypical antipsychotics compared with placebo for agitation andaggression in Alzheimer’s disease dementia, low-dose risperidone is most promising and aripiprazole can be expected to be
as effective as risperidone, while the effect of olanzapine is variable, and quetiapine is not effective 2).
A systematic review on antidepressants finds little research and insufficient evidence, but the effectiveness of sertraline,
escitalopram, and trazodone has been reported 3). Carbamazepine can also be expected to be effective 2). A multicenter study inJapan has reported the effectiveness of Yokukansan 4). Tiapride is also reported to be effective for agitation and aggression 5). Useof tiapride may be considered because it is covered by health insurance in Japan for aggressive behavior and hyperphrenia
associated with the sequelae of cerebral infarction.

▪ References
1) Livingston G, Kelly L, Lewis-Holmes E, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised
controlled trials. Br J Psychiatry. 2014; 205(6): 436-442.
2) Ballard C, Corbett A. Agitation and aggression in people with Alzheimer’s disease. Curr Opin Psychiatry. 2013; 26(3): 252-259.
3) Seitz DP, Adunuri N, Gill SS, et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011; (2): CD008191.
4) Mizukami K, Asada T, Kinoshita T, et al. A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatmentof the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol. 2009; 12(2): 191-199.
5) Allain H, Dautzenberg PH, Maurer K, et al. Double blind study of tiapride versus haloperidol and placebo in agitation and aggressiveness in elderly
patients with cognitive impairment. Psychopharmacology (Berl). 2000; 148(4): 361-366.

▪ Search formulaNon-pharmacological therapies
PubMed search: October 2, 2015 (Friday)#1 (“Dementia/therapy” [Majr] OR dementia [TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration” [TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR

46

Clinical Practice Guideline for Dementia 2017

“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [Mesh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indifference* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation [TI] OR “Irritable Mood” [Mesh] OR irritability [TI] OR“Delusions” [Mesh] OR delusion* [TI] OR “Hallucinations” [Mesh] OR hallucination* [TI] OR “Depression” [Mesh] OR depression [TI] OR
dysphoria [TI] OR “Wandering Behavior” [Mesh] OR wandering [TI]OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual
Behavior” [Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI] OR “inappropriate sexual behavior” [TI] OR restlessness[TI] OR(“Motor Activity” [Mesh]AND aberrant [TI]) OR “aberrant motor behaviour” [TI] OR “aberrant motor behavior” [TI] OR “Sleep
Disorders” [Mesh] OR “nighttime insomnia” [TI] OR “sleep disturbance” [TI] OR “daytime napping” [TI] OR “daytime sleepiness” [TI] OR“Apathy” [Mesh] OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indi­fference OR aggression OR agitation OR
irritability OR delusion* OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour”
OR “inappropriate sexual behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR“sleep disturbance” OR “daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR frontotemporal lobar degeneration/TI OR “frontotemporal lobar degeneration”/TI)
AND((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR 非Pharmacotherapy/TI OR Nonpharmacological treatment/TI OR validation therapy/TH OR validation therapy/TI OR “validation therapy”/TI OR Reality Orientation/TH OR“Reality Orientation”/TI OR reminiscence/TH OR reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH OR Music therapy/TI
OR “music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR Aromatherapy/TI OR“aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise therapy/TH OR
Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR Physical exercise/
TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive training/TI OR“cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR “stimulation
therapy”/TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver /TH OR Caregiver/TI)
AND (Education/TI OR Intervention/TI)) OR (caregiver/TI) AND (“psycho-education”/TI OR intervention/TI)) OR Nursing care service/TH
OR Nursing care service/TI OR “dementia care service”/TI OR day care/TH OR day care/TI OR “adult day service”/TI OR “dementia day
service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND(Anxiety/TH OR Anxiety/TI OR Indifference/TI OR
Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/ TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness)OR Inappropriate sexual behavior/TI OR Sexual perversion/
TH OR ((Deviation OR Abnormality)AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleeping disturbance/TI OR
Dyssomnia/TI OR Insomnia/TI OR Sleepiness/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug ­therapy” [Mesh]) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR “Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine, Kampo” [Mesh]
OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR (dementia OR “alzheimer disease” OR “alzheimer’s
disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine OR“selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”)
Ichushi search: June 22, 2015 (Monday)#1 (Dementia/TH OR Dementia/TI) AND ((SH = Pharmacotherapy) OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/
TI OR Therapeutic drug/ TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Aggression/TH OR Aggression/TI OR Psychomotor
agitation/TH OR Irritable mood/ TH)

Chapter 347

CQ 3B-3

What are the effective non-pharmacological therapies and pharmacotherapy
for hallucinations and delusions?
Recommendation
For persons with dementia who manifest hallucinations and delusions, the first step is to reduce their anxiety throughan approach of acceptance. In addition, when a specific person is the object of delusion, consider keeping a temporal andphysical distance from that person. Also consider the possibility that the drugs being taken may cause hallucinations anddelusions, and investigate this possibility. In patients with Alzheimer ’s disease dementia, if symptoms do not improve byanti-dementia drugs and the above methods, consider using atypical antipsychotics such as risperidone, olanzapine,quetiapine, and aripiprazole. Yokukansan may also be considered.
2C

Comment and evidence
For hallucinations and delusions, it is important to listen to the patients’ complaint first, and then give them a sense of
security in a receptive and sympathetic manner without denial or affirmation. It is also important to give them a role andsomething to live for.
When a specific person in the family is the subject of delusion, it is useful to utilize care services to keep a time andphysical distance between the patient and that person. If such intervention does not solve the problem, pharmacotherapy has
to be considered. For delusions in Alzheimer ’s disease dementia, try to administer anti-dementia drug. If the symptoms do
not improve, consider using antipsychotic drugs. However, since these drugs are used off-label, it is necessary to explain
carefully to the patients and families and pay attention to adverse events during use. In addition, even if a drug is effective,
it should not be taken casually. Bear in mind the need to reduce the risk of adverse effects by adjusting the dose or withdrawing
the drug when symptoms have improved.
Regarding the use of antipsychotic drugs in persons with dementia, effectiveness has been reported in a few studies withsmall numbers of cases, but no large-scale randomized controlled trial (RCT) has been reported 1-3). When using antipsychotic
drugs, atypical antipsychotics (risperidone, olanzapine, quetiapine, aripiprazole) are recommended.
For drugs other than antipsychotics, Yokukansan has been reported to be effective in a small number of cases 2).
Regarding pharmacotherapy for visual hallucinations in Parkinson’s disease with dementia (PDD) and dementia with
Lewy bodies (DLB), see CQ7-6.

▪ References
1) Cipriani G, Danti S, Vedovello M, et al. Understanding delusion in dementia: a review. Geriatr Gerontol Int. 2014; 14(1): 32-39.
2) Mizukami K. Pharmacotherapy for BPSD. Jpn J Gen Hosp Psychiatry. 2011; 23(1); 19-26. (In Japanese with English abstract)3) Shinagawa S, Nakajima S, Plitman E, et al. Psychosis in frontotemporal dementia. J Alzheimers Dis. 2014; 42(2); 485-499.

▪ Search formulaNon-pharmacological therapies
PubMed search: October 2, 2015 (Friday)#1 (“Dementia/therapy” [Majr] OR dementia [TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration” [TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [Mesh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indiff­erence* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation [TI] OR “Irritable Mood” [Mesh] OR irritability [TI] OR“Delusions” [Mesh] OR delusion* [TI] OR “Hallucinations” [Mesh] OR hallucination* [TI] OR “Depression” [Mesh] OR depression [TI] OR

48

Clinical Practice Guideline for Dementia 2017

dysphoria [TI] OR “Wandering Behavior” [Mesh] OR wandering [TI] OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual
Behavior” [Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI] OR “inappropriate sexual behavior” [TI] OR restlessness[TI] OR(“Motor Activity” [Mesh] AND aberrant [TI]) OR “aberrant motor behaviour” [TI] OR “aberrant motor behavior” [TI] OR “Sleep
Disorders” [Mesh] OR “nighttime insomnia” [TI] OR “sleep disturbance” [TI] OR “daytime napping” [TI] OR “daytime sleepiness” [TI] OR“Apathy” [Mesh] OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indi­fference OR aggression OR agitation OR
irritability OR delusion* OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour”
OR “inappropriate sexual behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR“sleep disturbance” OR “daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR Alzheimer/TI OR frontotemporal lobar degeneration/TI OR “frontotemporal lobar
degeneration”/TI) AND ((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR Pharmacotherapy/TI
OR Non-pharmacological treatment/TI OR Validation therapy/TH OR Validation therapy/TI OR “validation therapy”/TI OR Reality Orientation/
TH OR “Reality Orientation”/TI OR Reminiscence/TH OR Reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH OR Music
therapy/TI OR “music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR Aromatherapy/
TI OR “aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise therapy/TH
OR Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR Physicalexercise/TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive training/TI
OR “cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR “stimulation
therapy”/ TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver /TH OR Caregiver/TI)
AND (Education/TI OR Intervention/TI)) OR (caregiver/TI AND (“psycho-education”/TI OR intervention/TI)) OR Nursing care service/TH
OR Nursing care service/TI OR “dementia care service”/TI OR Day care/TH OR Day care/TI OR “adult day service”/TI OR “dementia day
service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND(Anxiety/TH OR Anxiety/TI OR Indifference/TI OR
Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/ TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual perversion/
TH OR ((Deviation OR Abnormality) AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleep disturbance/TI OR
Dyssomnia/TI OR Insomnia/TI OR Sleepiness/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 (Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug th­erapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR “Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh]OR “Medicine, Kampo” [Mesh]
OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease” OR “alzheimer’s
disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine OR“selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”)) AND (“Delusions” [Mesh] OR delusion* OR “Hallucinations” [Mesh] OR hallucination*)
Ichushi: June 22, (Monday)#1 (Dementia/TH OR Dementia/TI) AND ((SH = Pharmacotherapy)OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/TI
OR Therapeutic drug/ TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Hallucination/TH OR Hallucination/TI OR Delusion/TH
OR Delusion/TI)

Chapter 349

CQ 3B-4

What are the effective non-pharmacological therapies and pharmacotherapy
for depression?
Recommendation
For depressive symptoms, consider the situation of the person with dementia and communicate with a receptive attitude.
Regarding non-pharmacological interventions, utilization of social support, reminiscence therapy, and music therapy are
effective. In Japan, utilization of long-term care services is a realistic measure. If no improvement is observed after theabove interventions have been given for a certain period of time, consider using antidepressants such as selective serotonin
reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI).
2C

Comments and evidence
A systematic review clarifies that social support, classified as a non-pharmacological intervention, may improve depressive
symptoms in people with dementia 1).
Two randomized controlled trials (RCTs) have demonstrated the effectiveness of music therapy. Both individual therapy 2)
provided by music therapists and group music activity program 3) are effective, and both singing and music appreciation are also
effective. A meta-analysis also shows that reminiscence therapy has a moderate improvement effect in reducing depressive
symptoms in older people with dementia 4). For exercise therapy, a meta-analysis concludes with moderate confidence that there
is no effect on depression 5).
Regarding antidepressants, a systematic review of 10 RCTs and 3 meta-analyses finds that the effect of antidepressants fordepression in dementia is inconclusive 6). In addition, a meta-analysis of 6 RCTs on SSRI also does not support the effectivenessof SSRI for depression in dementia 7). Furthermore, mirtazapine is not effective 8). The observation periods in most of theabove studies on non-pharmacological interventions are 5-12 weeks. Therefore, if symptoms do not improve after 12 weeks
of non-pharmacological intervention, consider starting antidepressants. When selecting drug options, start with SSRI andSNRI that have few adverse effects.

▪ References
1) Leung P, Orrell M, Orgeta V. Social support group interventions in people with dementia and mild cognitive impairment: a systematic review of theliterature. Int J Geriatr Psychiatry. 2015; 30(1): 1-9.
2) Raglio A, Oasi O, Gianotti M, et al. Eff­ects of music therapy on psychological symptoms and heart rate variability in patients with dementia. A pilot
study. Curr Aging Sci. 2010; 3(3): 242-246.
3) Sarkamo T, Tervaniemi M, Laitinen S, et al. Cognitive, emotional, and social benefits of regular musical activities in early dementia: randomized
controlled study. Gerontologist. 2014; 54(4): 634-650.
4) Huang HC, Chen YT, Chen PY, et al. Reminiscence therapy improves cognitive functions and reduces depressive symptoms in elderly people withdementia: A meta-analysis of randomized controlled trial. J Am Med Dir Assoc. 2015; 16(12): 1087-1094.
5) Forbes D, Forbes SC, Blake CM, et al. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015; 4: CD006489.
6) Leong C. Antidepressants for depression in patients with dementia: a review of the literature. Consult Pharm. 2014; 29(4): 254-263.
7) Sepehry AA, Lee PE, Hsiung GY, et al. Eff­ect of selective serotonin reuptake inhibitors in Alzheimer’s disease with comorbid depression: a metaanalysis of depression and cognitive outcomes. Drugs Aging. 2012; 29(10): 793-806.
8) Banerjee S, Hellier J, Romeo R, et al. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial- a multicentre, randomised,double-blind, placebo-controlled trial of the clinical eff­ectiveness and cost-effectiveness of sertraline and mirtazapine. Health Technol Assess. 2013;17(7): 1-166.

▪ Search formulaNon-pharmacological therapies
PubMed search: October 2, 2015 (Friday)#1 (“Dementia/therapy” [Majr] OR dementia [TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration”[TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR

50

Clinical Practice Guideline for Dementia 2017

“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [sh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indi­fference* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation[TI] OR “Irritable Mood” [Mesh] OR irritability [TI] OR “Delusions”[Mesh] OR delusion*[TI] OR “Hallucinations” [Mesh] OR hallucination*[TI] OR “Depression” [Mesh] OR depression [TI] OR dysphoria [TI]
OR “Wandering Behavior” [Mesh] OR wandering [TI] OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual Behavior”[Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI]OR “inappropriate sexual behavior” [TI] OR restlessness [TI] OR(“Motor Activity” [Mesh]AND aberrant [TI]) OR “aberrant motor behaviour”[TI] OR “aberrant motor behavior” [TI] OR “Sleep Disorders”[Mesh] OR “nighttime insomnia” [TI] OR “sleep disturbance” [TI] OR “daytime napping” [TI]OR “daytime sleepiness” [TI] OR “Apathy” [Mesh]
OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indiff­erence OR aggression OR agitation OR irritability OR delusion*
OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour” OR “inappropriate sexual
behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR “sleep disturbance” OR“daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR Alzheimer/TI OR Frontotemporal lobar degeneration/TI OR “frontotemporal lobar
degeneration”/TI) AND ((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR Non-pharmacotherapy/
TI OR Non-pharmacological treatment/TI OR Validation therapy/TH OR Validation therapy/TI OR “validation therapy”/TI OR Reality
Orientation/TH OR “Reality Orientation”/TI OR Reminiscence/TH OR Reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH
OR Music therapy/TI OR “music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR
Aromatherapy/TI OR “aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise
therapy/TH OR Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR
Physical exercise/TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive
training/TI OR “cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR“stimulation therapy”/ TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver /TH OR
Caregiver/TI) AND (Education/TI OR Intervention/TI)) OR (caregiver/TI AND (“psycho-education”/TI OR intervention/TI)) OR Nursing careservice/TH OR Nursing care service/TI OR “dementia care service”/TI OR Day care/TH OR Day care/TI OR “adult day service”/TI OR “dementia
day service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND(Anxiety/TH OR Anxiety/TI OR Indifference/TI
OR Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/ TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual perversion/
TH OR ((Deviation OR Abnormality) AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleep disturbance/TI OR
Dyssomnia/TI OR Insomnia/TI OR Sleepiness/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 (Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug ­t herapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR “Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine, Kampo” [Mesh]
OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease” OR “alzheimer’s
disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine OR“selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”)) AND (“Depression” [Mesh] OR depression OR dysphoria)
Ichushi search: June 22, 2015 (Monday)#1 (Dementia/TH OR Dementia/TI) AND ((SH = Pharmacotherapy) OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/
TI OR Therapeutic drug/ TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Depression/TH or Depression/TI)

Chapter 3

51

CQ 3B-5

What are the effective non-pharmacological therapies and pharmacotherapy
for wandering?
Recommendation
Consider the reason or cause of wandering from the viewpoint of the patient with dementia and take preventive
measures. For a person with dementia who wanders frequently, make a plan to facilitate finding of the missing person.
Regarding pharmacotherapy, risperidone may be considered, but the scientific evidence is insufficient. Tiapride may also
be considered, because this drug is covered by health insurance in Japan for wandering associated with the sequelae of
cerebral infarction. However, if the above interventions and treatments do not solve the issue, consider using nursing careservices such as institutional care service.
2C

Comments and evidence
To address wandering in patients with dementia, non-pharmacological interventions are the first choice, and when they
are not effective, pharmacotherapy is selected. Many of the drugs used for these behavioral symptoms are used off-label.
Therefore, it is necessary to use with caution, giving sufficient explanations to the patients and families and paying attention
to adverse events during use. In addition, even if the drug is effective, it should not be used casually. Keep in mind to decrease
the risk of adverse effects by reducing the dose or withdrawing the drug when symptoms have improved.

Wandering
Various actions of a person with dementia can be recognized by others as signs of wandering. First, consider the nature,reason and cause of the actions from the viewpoint of the person with dementia, and take preventive measures. While
wandering, the persons with dementia are often tense and confused. It is important to listen to them and make them feelreassured. For persons with dementia who frequently wander, it is important to take precautions even while they are calm.
For example, dress them in easily recognizable clothes, write contact information on the clothes and shoes they wear, and use
devices such as global positioning systems (GPS). Moreover, it is useful to obtain support from neighbors and to register inprograms for wandering persons in municipalities that have such mechanisms. Although there is no study that evaluates theeffectiveness of pharmacotherapy focusing on wandering in dementia patients, a randomized controlled trial (RCT) thatcompares the effects of risperidone on behavioral and psychological symptoms of dementia (BPSD) reports significant
improvement for wandering 1). Therefore, use of risperidone may be considered. Tiapride may also be used, as its indication
for wandering associated with the sequelae of cerebral infarction is covered by health insurance in Japan. In the case of
wandering associated with agitation, drugs for agitation may be considered (see CQ3B-2). In addition, improvement of sleep/
wake pattern has been reported to reduce wandering 2). Therefore, if the patient also has sleep disturbance, consider treatment
for sleep disturbance (see CQ3B-6). If there is no improvement despite various treatments and interventions, consider
utilizing institutional care services.

▪ References
1) Rabinowitz J, Katz IR, De Deyn PP, et al. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy withrisperidone. J Clin Psychiatry. 2004; 65(10): 1329-1334.
2) Meguro K, Meguro M, Tanaka Y, et al. Risperidone is eff­ective for wandering and disturbed sleep/wake patterns in Alzheimer’s disease. J Geriatr
Psychiatry Neurol. 2004; 17(2): 61-67.

▪ Search formulaNon-pharmacological therapies
PubMed search: October 2, 2015 (Friday)#1 (“Dementia/therapy” [Majr] OR dementia [TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration” [TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR

52

Clinical Practice Guideline for Dementia 2017

“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [sh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indi­fference* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation [TI] OR “Irritable Mood” [Mesh] OR irritability [TI] OR“Delusions” [Mesh] OR delusion* [TI] OR “Hallucinations” [Mesh] OR hallucination* [TI] OR “Depression” [Mesh] OR depression [TI] OR
dysphoria [TI] OR “Wandering Behavior” [Mesh] OR wandering [TI] OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual
Behavior” [Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI]OR “inappropriate sexual behavior” [TI] OR restlessness[TI] OR (“Motor Activity” [Mesh] AND aberrant[TI]) OR “aberrant motor behaviour” [TI] OR “aberrant motor behavior” [TI] OR “Sleep
Disorders” [Mesh] OR “nighttime insomnia” [TI] OR “sleep disturbance”[TI] OR “daytime napping” [TI] OR “daytime sleepiness” [TI] OR“Apathy” [Mesh] OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indiff­erence OR aggression OR agitation OR
irritability OR delusion* OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour”
OR “inappropriate sexual behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR“sleep disturbance” OR “daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR Alzheimer/TI OR frontotemporal lobar degeneration/TI OR “frontotemporal lobar
degeneration”/TI) AND ((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR Non-pharmacologicaltreatment/TI OR Validation therapy/TH OR Validation therapy/TI OR “validation therapy”/TI OR Reality Orientation/TH OR “Reality
Orientation”/TI OR Reminiscence/TH OR Reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH OR Music therapy/TI OR“music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR Aromatherapy/TI OR“aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise therapy/TH OR
Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR Physical exercise/
TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive training/TI OR“cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR “stimulation
therapy”/ TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver /TH OR Caregiver/TI)
AND (Education/TI OR Intervention/TI)) OR (caregiver/TI AND (“psycho-education”/TI OR intervention/TI)) OR Nursing care service/TH
OR Nursing care service/TI OR “dementia care service”/TI OR Day care/TH OR Day care/TI OR “adult day service”/TI OR “dementia day
service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND (Anxiety/TH OR Anxiety/TI OR Indifference/TI OR
Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/ TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual perversion/
TH OR ((Deviation OR Abnormality) AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleep disturbance/TI OR
Dyssomnia/TI OR Insomnia/TI OR Sleepiness/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 ((Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug therapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR“Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine,
Kampo”[Mesh]OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease” OR“alzheimer’s disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine
OR “selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”))) AND (“Wandering Behavior” [Mesh]OR wandering [TI] OR wandering OR “Inhibition(Psychology)” [Mesh] OR disinhibition* [TI] OR disinhibition* OR (“Sexual Behavior” [Mesh] AND inappropriate) OR “inappropriate sexual
behaviour” OR “inappropriate sexual behavior” OR (“Psychomotor Agitation” [Mesh] AND restlessness) OR restlessness OR (“Motor Activity”[Mesh] AND aberrant)OR “aberrant motor behaviour” OR “aberrant motor behavior”)
Ichushi search: June 22, 2015 (Monday)#1 (Dementia/TH OR Dementia/TI)AND((SH = Pharmacotherapy)OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/TI
OR Therapeutic drug/ TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual
perversion/TH OR ((Deviation OR Abnormality) AND Sexual behavior/TH))

Chapter 3

53

CQ 3B-6

What are the effective non-pharmacological therapies and pharmacotherapy
for sleep disturbance (excluding REM sleep behavior disorder)?
Recommendation
First, assess sleep disturbance accurately and conduct differential diagnosis. If there are physical symptoms (such as
pain, urinary frequency, and itchiness), psychological or social stress, stimulant-containing products, and drugs that may
contribute to sleep disturbance, mitigate those factors. In addition, encourage the patient to do sunbathing and physicalactivities during the day, and to attempt to improve the sleep environment. If possible, consider bright light therapy. For
pharmacotherapy, use of trazodone or risperidone may be considered. However, benzodiazepines as sleep inducing agentsare not recommended because of the risk of adverse events such as sedation and falls.
2C

Comment and evidence
In Alzheimer’s disease dementia and dementia with Lewy bodies, complex sleep disturbances such as insomnia,
hypersomnia, and sleep/wake rhythm disturbances may occur 1). In addition, the patients tend to have various conditions
such as sleep apnea syndrome, restless legs syndrome (RLS), periodic limb movement disorder, nocturnal leg cramp, andREM sleep behavior disorder. Therefore, it is important to assess sleep disturbance accurately and conduct differential
diagnosis. Furthermore, sleep disturbance may become chronic due to diverse underlying factors including physicalsymptoms (such as pain, urinary frequency, and itchiness), exacerbation of psychiatric symptoms, increased psychologicaland social stress, and influence by stimulant-containing products (such as alcohol, caffeine, and nicotine) and drugs.
Therefore, removal of these factors is also important.
In a systematic review of 38 pharmacological or non-pharmacological intervention studies targeting sleep disturbances inpatients with mild to moderate Alzheimer’s disease dementia, bright light therapy gives the best results and is effective in
reducing nocturnal awakening and prolonging nighttime sleep 2). In addition, multi-faceted interventions including daytime
sunlight exposure, physical activity, exercise, restriction of daytime napping, structured bedtime routines (performing
certain actions in a predetermined order before going to bed), improvement of sleep environment such as reducing noise andlight at night are also effective in improving sleep disturbance. The use of pharmacotherapy is limited when consideringsafety. In particular, although sedative-hypnotic medications represented by benzodiazepines are widely used clinically, there
are few data supporting their use. Conversely, they may cause sedation, daytime somnolence, falls, confusion, and amnesia,
and should therefore be used with caution. Two randomized controlled trials (RCTs) have shown the effectiveness ofrisperidone, and this drug may be considered.
It has been reported that trazodone given to patients with Alzheimer’s disease dementia at a dose of 50 mg per day for 2
weeks prolongs total sleeping time and improves sleep efficiency. Use of this drug may be considered 3).
Regardless of which drugs are being used, even if they prove to be effective, they should not be used casually. Always
remember to reduce the risk of adverse effects by reducing the dose or withdrawing the drug when symptoms have improved.

▪ References
1) Mishima K (Ed.) Clinical Guidelines for Proper Use and Cessation of Hypnotics. Tokyo: Jibo; 2014. (In Japanese)
2) Salami O, Lyketsos C, Rao V. Treatment of sleep disturbance in Alzheimer’s dementia. Int J Geriatr Psychiatry. 2011; 26(8): 771-782.
3) McCleery J, Cohen DA, Sharpley AL. Pharmacotherapies for sleep disturbances in Alzheimer’s disease. Cochrane Database Syst Rev. 2014; (3):CD009178.

▪ Search formulaNon-pharmacological therapies
PubMed search: October 2, 2015 (Friday)#1 (“Dementia/therapy” [Majr] OR dementia[ TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration” [TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR

54

Clinical Practice Guideline for Dementia 2017

“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [sh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indi­fference* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation [TI] OR “Irritable Mood” [Mesh]OR irritability [TI] OR “Delusions”[Mesh] OR delusion* [TI] OR “Hallucinations” [Mesh] OR hallucination* [TI] OR “Depression” [Mesh] OR depression [TI] OR dysphoria [TI]
OR “Wandering Behavior” [Mesh] OR wandering [TI] OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual Behavior”[Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI] OR “inappropriate sexual behavior” [TI] OR restlessness [TI]
OR(“Motor Activity” [Mesh] AND aberrant[TI]) OR “aberrant motor behaviour”[TI] OR “aberrant motor behavior” [TI] OR “Sleep Disorders”[Mesh] OR “nighttime insomnia” [TI] OR “sleep disturbance” [TI] OR “daytime napping” [TI] OR “daytime sleepiness” [TI] OR “Apathy”[Mesh] OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indiff­erence OR aggression OR agitation OR irritability OR
delusion* OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour” OR “inappropriate
sexual behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR “sleep disturbance”
OR “daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR Frontotemporal lobar degeneration/TI OR “frontotemporal lobar degeneration”/TI)
AND((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR Non-pharmacotherapy/TI OR Nonpharmacological treatment/TI OR Validation therapy/TH OR Validation therapy/TI OR “validation therapy”/TI OR Reality Orientation/TH OR“Reality Orientation”/TI OR Reminiscence/TH OR Reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH OR Music therapy/
TI OR “music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR Aromatherapy/TI OR“aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise therapy/TH OR
Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR Physical exercise/
TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive training/TI OR“cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR “stimulation
therapy”/ TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver /TH OR Caregiver/TI)
AND (Education/TI OR Intervention/TI)) OR(caregiver/TI AND (“psycho-education”/TI OR intervention/TI)) OR Nursing care service/TH
OR Nursing care service/TI OR “dementia care service”/TI OR Day care/TH OR Day care/TI OR “adult day service”/TI OR “dementia day
service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND (Anxiety/TH OR Anxiety/TI OR Indifference/TI OR
Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/ TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual perversion/
TH OR((Deviation OR Abnormality) AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleep disturbance/TI OR
Dyssomnia/TI OR Insomnia/TI OR Somnolence/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 (Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug th­erapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR“Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine,
Kampo” [Mesh] OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease”
OR “alzheimer’s disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR
benzodiazepine OR “selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “moodstabilizer” OR anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR“orexin receptor antagonist” OR “melatonin receptor agonist”)) AND (“Sleep Disorders” [Mesh] OR “nighttime insomnia” OR “sleep disturbance”
OR “daytime napping” OR “daytime sleepiness”)
Ichushi search: June 23, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI AND ((SH = Pharmacotherapy) OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/TI
OR Therapeutic drug/TI OR Kampo medicine/TH OR Antipsychotics/TH)) AND (Sleep disorder/TH or Sleep disorder/TI OR Sleep disturbance/
TI OR Dyssomnia/TI OR Insomnia/TI OR Somnolence/TI)

Chapter 3

55

CQ 3B-7

What are the effective non-pharmacological therapies and pharmacotherapy
for apathy?
Recommendation
As a non-pharmacological intervention for apathy, therapeutic activities customized for individual patients withdementia are suggested to be effectiveness. In Japan, incorporating this approach as a program in dementia care service
seems to be a realistic measure. For pharmacotherapy, cholinesterase inhibitor is the first choice if indicated for the disease.
Memantine may be considered, but antidepressants and antiepileptic drugs have not been reported to be effective.

2C

Comments and evidence
Apathy is a state of reduced spontaneity, initiative, interest, concern, motivation, and emotion. Because these are notpositive symptoms such as delusion and irritability, they tend to be misunderstood as posing less burden on nursing care.
However, since patients may gradually stop executing actions that should be taken in daily life, or do not respond tocommunication from other persons, apathy is a symptom that requires treatment.
To verify the effects of non-pharmacological interventions for apathy, a systematic review of 56 studies suggests thattherapeutic activities, particularly those planned to match the level and interest of the individual, can be expected to bebeneficial 1). Specifically, these activities involve participant-led interactive discussions, and activities such as solving puzzles,
making salad, sorting beads, woodwork, and catching ball are conducted while an occupational therapist provides guidance
to the family caregivers. In Japan, receiving this treatment as a program in dementia care service seems to be a realistic
measure.
A systematic review that summarizes the effects of pharmacotherapy confirms the benefit of cholinesterase inhibitors forapathy, and recommends these drugs as first-line drug for patients with dementia if there is no contraindication 2). Memantine
may also be effective.

▪ References
1) Brodaty H, Burns K. Nonpharmacological management of apathy in dementia: a systematic review. Am J Geriatr Psychiatry. 2012; 20(7): 549-564.
2) Berman K, Brodaty H, Withall A, et al. Pharmacologic treatment of apathy in dementia. Am J Geriatr Psychiatry. 2012; 20(2): 104-122.

▪ Search formulaNon-pharmacological therapies
PubMed search: October 2, 2015 (Friday)#1 (“Dementia/therapy” [Majr] OR dementia [TI] OR “Alzheimer disease” [TI] OR “Alzheimer’s disease” [TI] OR “vascular dementia” [TI] OR“Lewy Body” [TI] OR “frontotemporal dementia” [TI] OR “frontotemporal lobar degeneration” [TI]) AND (“nonpharmacological therapy” OR“non pharmacological therapy” OR “nonpharmacologic therapy” OR “non pharmacologic therapy” OR “nonpharmacological treatment” OR “nonpharmacological treatment” OR “nonpharmacologic treatment” OR “non pharmacologic treatment” OR nonpharmacological intervention* OR
non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR “nonpharmacologicalmanagement” OR “non pharmacological management” OR “nonpharmacologic management” OR “non pharmacologic management” OR“validation therapy” OR “reality orientation” OR “reminiscence therapy” OR “music therapy” OR “light therapy” OR “tactile therapy” OR“aromatherapy” OR “occupational therapy” OR “exercise therapy” OR “exercise training” OR “exercise program” OR “physical exercise” OR“cognitive training” OR “rehabilitation” OR “stimulation therapy” OR “psychological therapy” OR (caregiver* AND (“psycho-education” OR
intervention)) OR “dementia care service” OR “adult day service” OR “dementia day service” OR “Rehabilitation” [Mesh] OR “Phototherapy”[Mesh] OR “Exercise” [Mesh] OR “rehabilitation” [sh] OR “Psychotherapy” [Mesh] OR (“Caregivers” [Mesh] AND (“psycho-education” OR
intervention)) OR “Touch” [Mesh] OR “Day Care” [Mesh]) AND (“Anxiety” [Mesh] OR anxiety [TI] OR indi­fference* [TI] OR “Aggression”[Mesh] OR aggression [TI] OR “Psychomotor Agitation” [Mesh] OR agitation [TI] OR “Irritable Mood” [Mesh] OR irritability [TI] OR“Delusions” [Mesh] OR delusion* [TI] OR “Hallucinations” [Mesh] OR hallucination* [TI] OR “Depression” [Mesh] OR depression [TI] OR
dysphoria [TI] OR “Wandering Behavior” [Mesh] OR wandering [TI] OR “Inhibition (Psychology)” [Mesh] OR disinhibition* [TI] OR (“Sexual
Behavior” [Mesh] AND inappropriate [TI]) OR “inappropriate sexual behaviour” [TI] OR “inappropriate sexual behavior” [TI] OR restlessness[TI] OR (“Motor Activity” [Mesh] AND aberrant [TI])OR “aberrant motor behaviour” [TI] OR “aberrant motor behavior” [TI] OR “Sleep
Disorders” [Mesh] OR “nighttime insomnia”[TI] OR “sleep disturbance” [TI] OR “daytime napping” [TI] OR “daytime sleepiness” [TI] OR“Apathy” [Mesh] OR apathy [TI] OR “Delirium” [Mesh] OR delirium [TI] OR ((anxiety OR indiff­erence OR aggression OR agitation OR

56

Clinical Practice Guideline for Dementia 2017

irritability OR delusion* OR hallucination* OR depression OR dysphoria OR wandering OR disinhibition* OR “inappropriate sexual behaviour”
OR “inappropriate sexual behavior” OR restlessness OR “aberrant motor behaviour” OR “aberrant motor behavior” OR “nighttime insomnia” OR“sleep disturbance” OR “daytime napping” OR “daytime sleepiness” OR apathy OR delirium) AND (in process [SB] OR publisher [SB])))
Ichushi search: October 2, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI OR Alzheimer/TI OR Alzheimer/TI OR Frontotemporal lobar degeneration/TI OR “frontotemporal lobar
degeneration”/TI) AND ((SH = Surgical therapy, transplantation, dietary therapy, radiotherapy, nursing, rehabilitation) OR Non-pharmacotherapy/
TI OR Non-pharmacological treatment/TI OR Validation therapy/TH OR Validation therapy/TI OR “validation therapy”/TI OR Reality
Orientation/TH OR “Reality Orientation”/TI OR Reminiscence/TH OR Reminiscence/TI OR “reminiscence therapy”/TI OR Music therapy/TH
OR Music therapy/TI OR “music therapy”/TI OR Light therapy/TH OR Light therapy/TI OR “light therapy”/TI OR Aromatherapy/TH OR
Aromatherapy/TI OR “aromatherapy”/TI OR Occupational therapy/TH OR Occupational therapy/ TI OR “occupational therapy”/TI OR Exercise
therapy/TH OR Exercise therapy/TI OR “exercise therapy”/TI OR Exercise training/TH OR Exercise training/TI OR “exercise training”/TI OR
Physical exercise/TH OR Physical exercise/TI OR “physical exercise”/TI OR “exercise program”/TI OR Cognitive training/TH OR Cognitive
training/TI OR “cognitive training”/TI OR Rehabilitation/TH OR Rehabilitation/TI OR “rehabilitation”/TI OR Stimulation therapy/TI OR“stimulation therapy”/TI OR Psychological therapy/TH OR Psychological therapy/TI OR “psychological therapy”/TI OR ((Caregiver /TH OR
Caregiver/TI) AND (Education/TI OR Intervention/TI)) OR (caregiver/TI AND (“psycho-education”/TI OR intervention/TI)) OR Nursing careservice/TH OR Nursing care service/TI OR “dementia care service”/TI OR Day care/TH OR Day care/TI OR “adult day service”/TI OR “dementia
day service”/TI OR Therapeutic touch/TH OR “tactile therapy”/TI OR Tactile care/TI) AND (Anxiety/TH OR Anxiety/TI OR Indifference/TI
OR Aggression/TH OR Aggression/TI OR Psychomotor agitation/TH OR Irritable mood/ TH OR Hallucination/TH OR Hallucination/TI OR
Delusion/TH OR Delusion/TI OR Depression/TH or Depression/TI or Depression/TI OR Violence/TH or Violence/TI OR Wandering/TH or
Wandering/TI OR Restlessness/TI OR (Psychomotor agitation/TH AND Restlessness) OR Inappropriate sexual behavior/TI OR Sexual perversion/
TH OR ((Deviation OR Abnormality)AND Sexual behavior/TH) OR Sleep disorder/TH or Sleep disorder/TI OR Sleep disturbance/TI OR
Dyssomnia/TI OR Insomnia/TI OR Somnolence/TI OR Apathy/TH or Apathy/TI OR Delirium/TH or Delirium/TI)
Pharmacotherapy
PubMed search: June 23, 2015 (Tuesday)#1 (Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug therapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR “Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine, Kampo” [Mesh]
OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease” OR “alzheimer’s
disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine OR“selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”)) AND (“Apathy” [Mesh] OR apathy)
Ichushi search: June 23, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI) AND ((SH = Pharmacotherapy) OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/
TI OR Therapeutic drug/ TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Apathy/TH OR Apathy/TI)

Chapter 357

C | Interventions for Coexisting Diseases
CQ 3C-1

How is delirium treated?
Recommendation
Always remember to prevent delirium. When delirium has emerged, treat or remove the direct causative or inducing
factors. If symptoms do not respond to these interventions and treatments, consider treatment with atypical antipsychotics
such as quetiapine, perospirone, risperidone, and olanzapine. Also consider hospitalization for the purposes of detailed
investigations of the cause of delirium, smooth implementation of treatment, and ensuring safety of the patient. Clinicalguidelines for delirium have been prepared by the Japanese Society of General Hospital Psychiatry, refer to the guidelines
as needed.
2C

Comments and evidence

Since dementia is a risk factor for the development of delirium, it is necessary to be always vigilant for early detection andtreatment of delirium. The background factors of delirium include the following: (1) predisposing factors (current or past historyof organic brain disorder, old age); (2) precipitating factors (environmental factors such as hospitalization and noise; physicalfactors such as pain, dehydration, and malnutrition; sensory factors such as decreased vision and hearing; mental factors such as
psychological stress and anxiety; sleep-related factors such as disrupted circadian rhythm; (3) direct factors that may inducedelirium even as a single factor (stroke, electrolyte abnormality, infection, initiation or withdrawal of drug use) 1).
For treatment of delirium in dementia, refer to the clinical guidelines on delirium prepared by the Delirium Guideline
Revision Group of Japanese Society of General Hospital Psychiatry 2). First, always try to remove the precipitating factors.
Also, treat the direct factor, if possible. If delirium does not improve after these treatments, consider atypical antipsychotics(quetiapine, perospirone, risperidone, and olanzapine). The former two are recommended from the viewpoint of short halflife. The latter two have the advantage of being a liquid formulation and an orally disintegrating tablet, respectively. Use
haloperidol injection if intake of oral medication is difficult. Use the minimum required dose, and in principle administerin the evening. For treatment of delirium, also consider hospitalization for the purposes of detailed investigations of thecause, ensuring safety of the patient, smooth implementation of treatment, and provision of a calm environment.
In a multicenter randomized controlled trial (RCT) conducted in Japan, the frequency of delirium is reduced by taking ramelteon
from the time of admission 3). Therefore use of this drug may be considered. All of the drugs mentioned above are used off-label.
When prescribing these drugs, it is necessary to explain in detail to the patients and families, and to be aware of adverse events.

▪ References

1) Lipowski ZJ. Delirium: acute confusional states. London: Oxford Univ Press; 1990.
2) Japanese Society of General Hospital Psychiatry Delirium Guideline Revision Group. Japanese Society of General Hospital Psychiatry Treatment
Guideline 1: Treatment Guidelines for Delirium, Second Edition: Clinical Guidelines for Delirium. Tokyo: Seiwa Shoten; 2015. (In Japanese)
3) Hatta K, Kishi Y, Wada K, et al. Preventive e­ffects of ramelteon on delirium: a randomized placebo-controlled trial. JAMA Psychiatry. 2014; 71(4):397-403.

▪ Search formula

PubMed search: June 23, 2015 (Tuesday)#1 ((Dementia [Mesh] AND (“drug therapy” [subheading] OR “Drug therapy” [Mesh])) OR (“Dementia/therapy” [Mesh] AND (“Antipsychotic
Agents” [Mesh] OR “Benzodiazepines” [Mesh] OR “Serotonin Uptake Inhibitors” [Mesh] OR “Antidepressive Agents” [Mesh] OR “Anticonvulsants”[Mesh] OR “Anticonvulsants” [PA] OR “Yi-Gan San” [Supplementary Concept] OR “Herbal Medicine” [Mesh] OR “Medicine, Kampo” [Mesh]
OR “ramelteon” [Supplementary Concept] OR “suvorexant” [Supplementary Concept])) OR ((dementia OR “alzheimer disease” OR “alzheimer’s
disease” OR “frontotemporal lobar degeneration”) AND (pharmacological OR drug OR medicine OR antipsychotics OR benzodiazepine OR“selective serotonin reuptake inhibitors” OR “serotonin-norepinephrine reuptake inhibitors” OR antidepressant* OR “mood stabilizer” OR
anticonvulsant* OR Yokukansan OR “Japanese herbal” OR “traditional herbal” OR kampo OR ramelteon OR suvorexant OR “orexin receptor
antagonist” OR “melatonin receptor agonist”))) AND (“Delirium” [Mesh]OR delirium)
Ichushi search: June 23, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI) AND ((SH = Pharmacotherapy)OR Pharmacotherapy/TH OR Drug treatment/TI OR Pharmacotherapy/TI
OR Therapeutic drug/ TI OR Kampo medicine/TH OR Antipsychotics/TH) AND (Delirium/TH or Delirium/TI)

58

Clinical Practice Guideline for Dementia 2017

CQ 3C-2

How epilepsy including seizures should be treated in patients with dementia?
Recommendation
The former antiepileptic drugs may worsen cognitive function, and should be used with caution in older patients withdementia. Novel antiepileptic drugs are relatively well tolerated and effective if the drug titration is applied.
2C

Comments and evidence
In dementia patients, the risk of both generalized and partial seizures is six times higher than in the control group 1, 2).
Especially in Alzheimer’s disease, the accumulation of amyloid β (Aβ) induces hyperexcitation of the cortical network in the
hippocampus, resulting in cognitive impairment, and the hippocampus can be the focus of epileptic seizures at the sametime 3, 4). In patients with Alzheimer’s disease, epilepsy with seizure focus in temporal lobe is common, and transient memory
impairment tends to occur especially if cognitive decline occurs at a younger age 5). In familial Alzheimer’s disease, several
cases with seizures and myoclonus have been reported 4). Cheng et al. 6) compared the age-adjusted annual incidence of
epilepsy between control and Alzheimer’s disease, and reported that the risk of epilepsy is increased by 1.85 times in patientswith Alzheimer’s disease at 3.6 years after the onset of dementia 6).
Because epileptic seizures worsen the prognosis of patients with dementia due to the higher risk of falls, trauma, and death,appropriate treatment with anti-epileptic drugs is required. However, the semiology of seizures is often non-convulsive,
subtle, and diverse, and often not recognized as seizures by the patient or the caregiver, which makes the diagnosis difficult.
Therefore, once a diagnosis of epilepsy is confirmed and the risk of seizure recurrence is high, it is necessary to startantiepileptic drug with monotherapy in a small dose at first and then upwardly titrating slowly 7). Since carbamazepine has
many drug interactions and adverse effects including cardiac conduction disorder, hyponatremia, and over-sedation, it
should be used with caution in older patients. Benzodiazepines, primidone, and phenobarbital are not recommended because
they worsen cognitive function. Sodium valproate has little effect on cognitive function, and it is effective for convulsive
seizures in older patients and for behavioral and psychological symptoms of dementia such as irritability, aggression andmood disorders.
New antiepileptic drugs (lamotrigine, levetiracetam, gabapentin, topiramate) are effective for seizures in older patientsand cause few adverse events. Among them, lamotrigine and levetiracetam are effective for epilepsy in patients with amnestic
mild cognitive impairment or early Alzheimer’s disease 5). In Japan, monotherapy of these drug is also indicated for thetreatment of epilepsy. Rowan et al. 8) recommend lamotrigine and gabapentin as antiepileptic drugs for older people withdementia, because they have less adverse effects compared with carbamazepine. Levetiracetam has been shown to be effective
and safe also in post-stroke epilepsy patients, and have less effect on cognitive function than carbamazepine 9).
In general, since older people often have lower serum albumin and liver and kidney dysfunctions, serum levels ofantiepileptic drugs can be readily elevated. Therefore, monotherapy of antiepileptic drugs starting with a low dose is highly
recommended. In addition, careful attention should be paid for drug interactions in older patients with dementia, because
they are usually taking multiple drugs.

▪ References
1) Hauser WA, Annegers JF, Rocca WA. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota.
Mayo Clin Proc. 1996; 71(6): 576-586.
2) Hesdor­er DC, Hauser WA, Annegers JF, et al. Dementia and adult-onset unprovoked seizures. Neurology. 1996; 46(3): 727-730.
3) Bell JS, Lonnroos E, Koivisto AM, et al. Use of antiepileptic drugs among community-dwelling persons with Alzheimer’s disease in Finland. J
Alzheimers Dis. 2011; 26(2): 231-237.
4) Born HA. Seizures in Alzheimer’s disease. Neuroscience. 2015; 286: 251-263.
5) Vossel KA, Beagle AJ, Rabinovici GD, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013; 70(9):1158-1166.
6) Cheng CH, Liu CJ, Ou SM, et al. Incidence and risk of seizures in Alzheimer’s disease: A nationwide population-based cohort study. Epilepsy Res.
2015; 115: 63-66.
7) Hommet C, Mondon K, Camus V, et al. Epilepsy and dementia in the elderly. Dement Geriatr Cogn Disord. 2008; 25(4): 293-300.
8) Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine.
Neurology. 2005; 64(11): 1868-1873.

Chapter 3599) Consoli D, Bosco D, Postorino P, et al. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective
randomized open-label study (EpIC Project). Cerebrovasc Dis. 2012; 34(4): 282-289.

▪ Search formula
PubMed search: July 5, 2015 (Sunday)#1 (“Dementia” [Mesh] OR dementia OR “Cognition Disorders” [Mesh] OR cognition disorder* OR cognitive disorder*) AND (“Seizures/therapy”[Mesh] OR (seizure* AND (therapy OR therapeutic OR treatment OR prophylaxis OR prevention)) OR (“Seizures” [Mesh] AND “Anticonvulsants/
therapeutic use” [Mesh]) OR (anticonvulsant* AND (therapy OR therapeutic OR treatment OR prophylaxis OR prevention)))Ichushi search: June 23, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI OR Cognitive impairment/TH OR Cognitive impairment/TI OR Cognitive function impairment/TI) AND(Epilepsy/TH OR Epilepsy/TI OR Epilepsy/TI) AND ((SH = Therapeutic use, treatment, drug treatment, surgical treatment, transplantation,
dietary treatment, psychiatric treatment, radiologic treatment) OR Treatment/TH OR Treatment/TI OR Therapy/TI OR Preventive/TI OR Anticonvulsive agent/TH OR Anti-convulsive agent/TI OR Anti-epileptic drug/TI OR Anti-convulsive agent/TI OR Anti-epileptic drug/TI OR Anticonvulsive drug/TI OR Anti-epileptic agent/TI OR Anti-convulsive drug/TI OR Anti-epileptic agent/TI)

60

Clinical Practice Guideline for Dementia 2017

CQ 3C-3

What are the interventions for dysphagia (including prevention of aspiration
pneumonia)?
Recommendation
To prevent the onset of aspiration pneumonia, angiotensin converting enzyme (ACE) inhibitor, amantadine, cilostazol(not covered by insurance), capsaicin, oral care, swallowing rehabilitation, chin down maneuver, maintaining sitting
position for 1 hour after eating, and influenza and pneumococcal vaccination are effective.
There is no data showing the usefulness of percutaneous endoscopic gastrostomy (PEG) in preventing aspiration
pneumonia or improving activities of daily living (ADL) and survival in patients with advanced stage dementia.

2D

Comments and evidenceIn frontotemporal lobar degeneration and Alzheimer’s disease dementia, abnormalities in eating behavior such as
overeating occur due to functional impairment of the limbic system and frontal lobe, and are particularly marked in theformer. Vascular dementia and dementia caused by parkinsonism often manifest impaired swallowing reflex, and aspiration
pneumonia is often caused by occult aspiration at night. On the other hand, in Alzheimer’s disease dementia, the swallowing
reflex is preserved until the late stage of the disease, and is often maintained even in a bed confined state.
Activation of the dopamine–substance P system is important for the prevention of aspiration pneumonia. Sensory stimulationof the oral cavity through oral care increases substance P, increases the sensitivity of the cough reflex, and consequently improves
the swallowing reflex 1, 2). Administration of ACE inhibitors that suppress substance P degradation is also useful 3). In addition,
cilostazol 4) and amantadine with dopamine release effect 5) have been reported to be effective in the prevention of aspiration
pneumonia. Furthermore, rivastigmine 6) and the Kampo herbal medicine “banxia houpo tang” 7) have been reported to improveswallowing function. Conversely, since cholinergic and dopaminergic systems act to maintain the swallowing function, drugs
with anticholinergic action and dopamine antagonistic action increase the risk of aspiration pneumonia 8).
In the advanced stage of dementia, use of PEG does not show benefit regarding survival duration, improvement of qualityof life (QOL), or reduction of aspiration pneumonia 9). Systematic reviews that evaluate the effect of PEG in dementia
patients with dysphagia have not found a survival-extending effect 10, 11).

▪ References
1) Yoshino A, Ebihara T, Ebihara S, et al. Daily oral care and risk factors for pneumonia among elderly nursing home patients. JAMA. 2001; 286(18):2235-2236.
2) Watando A, Ebihara S, Ebihara T, et al. Daily oral care and cough re­flex sensitivity in elderly nursing home patients. Chest. 2004; 126(4): 10661070.
3) Rafailidis PI, Matthaiou DK, Varbobitis I, et al. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol.
2008; 64(6): 565-573.
4) Shinohara Y. Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis.
2006; 22(1): 57-60.
5) Nakagawa T, Wada H, Sekizawa K, et al. Amantadine and pneumonia. Lancet. 1999; 353(9159): 1157.
6) Uwano C, Suzuki M, Aikawa T, Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer’s disease. J Am Geriatr
Soc. 2012; 60(10): 1979-1980.
7) Iwasaki K, Wang Q, Nakagawa T, et al. The traditional Chinese medicine banxia houpo tang improves swallowing refl­ex. Phytomedicine. 1999;
6(2): 103-106.
8) Wada H, Nakajoh K, Satoh-Nakagawa T, et al. Risk factors of aspiration pneumonia in Alzheimer’s disease patients. Gerontology. 2001; 47(5): 271276.
9) Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic
review. Arch Gerontol Geriatr. 2013; 56(1): 1-9.
10) Goldberg LS, Altman KW. The role of gastrostomy tube placement in advanced dementia with dysphagia: a critical review. Clin Interv Aging. 2014;
9: 1733-1739.
11) Candy B, Sampson EL, Jones L. Enteral tube feeding in older people with advanced dementia: findings from a Cochrane systematic review. Int J
Palliat Nurs. 2009; 15(8): 396-404.

Chapter 3

61▪ Search formula
PubMed search: July 15, 2015 (Wednesday)#1 (“Dementia” [Mesh] OR dementia OR Alzheimer* OR “Cognition Disorders” [Mesh] OR cognition disorder* OR cognitive disorder*) AND(“Deglutition Disorders/therapy” [Mesh] OR ((deglutition disorder* OR swallowing disorder* OR dysphagia) AND (therapy OR therapeutic OR
treatment OR prophylaxis OR prevention)) OR “Pneumonia, Aspiration/therapy” [Mesh] OR (aspiration pneumonia* AND (therapy OR
therapeutic OR treatment OR prophylaxis OR prevention)))Ichushi search: July 15, 2015 (Wednesday)#1 (Dementia/TH OR Dementia/TI OR Cognitive impairment/TH OR Cognitive impairment/TI OR Cognitive function impairment/TI) AND(dysphagia/TH or dysphagia/TI OR Pneumonia-aspiration/TH or aspiration pneumonia/TI) AND ((SH = Therapeutic use, treatment, drug
treatment, surgical treatment, transplantation, dietary treatment, psychiatric treatment, radiologic treatment, rehabilitation, prevention) OR
Treatment/TH OR Therapeutic use/TH OR Treatment/TI OR Therapy/TI OR Prevention/TI)

62

Clinical Practice Guideline for Dementia 2017

CQ 3C-4

What are the interventions for eating disorder and undernutrition?
Recommendation
In Alzheimer’s disease, eating difficulties may be caused by changes in eating behavior, loss of appetite, dysphagia, andautonomic disturbance. It is important to take history of the changes in body weight and quantity of food eaten; implement
nutritional assessment, prevention of aspiration, and review of medications; and examine the merits and demerits of oral
intake and tube feeding.
2C

Comments and evidence
Many people with dementia are affected by eating disorders, weight loss, and undernutrition.
Among people with mild Alzheimer’s disease, over 30% experience some changes in eating behavior, and 16% have lossof appetite 1). Riviere et al. 2) studied 224 people with moderate Alzheimer’s disease, and observed that 26% had eating
behavior disorders such as “getting up while eating” and “eating by hand”. In patients with severe dementia, 80% showed
weight loss, dysphagia, eating refusal, reduced food intake, and dehydration 2).
To investigate why people with Alzheimer’s disease lose appetite, Ismail et al. 3) observed reduced blood flow in various
regions including the anterior cingulate gyrus on blood flow SPECT, and speculated that these changes were related toappetite loss.
The adverse effects of cholinesterase inhibitors used as a treatment for Alzheimer’s disease include gastrointestinal
symptoms, although the symptoms are generally transient. There is a report suggesting that long-term administration ofthese agents may prevent weight loss 4).
In 2014, Goldberg et al. 5) conducted a systematic review on the usefulness of percutaneous endoscopic gastrostomy (PEG)
for severe dementia with dysphagia (publications from 1995 to 2012), and reported no evidence that PEG prolongs survival
long-term 5).
According to a review by Affoo et al. 6), while evidence suggests a possibility that dysphagia and autonomic nervous systemdysfunction may occur together in Alzheimer’s disease, the relationship between the two has not been clarified.

▪ References
1) Ikeda M, Brown J, Holland AJ, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer’s disease.
J Neurol Neurosurg Psychiatry, 2002; 73(4): 371-376.
2) Riviere S, Gillette-Guyonnet S, Andrieu S, et al. Cognitive function and caregiver burden: predictive factors for eating behaviour disorders in
Alzheimer’s disease. Int J Geriatr Psychiatry. 2002; 17(10): 950-955.
3) Ismail Z, Herrmann N, Rothenburg LS, et al. A functional neuroimaging study of appetite loss in Alzheimer’s disease. J Neurol Sci. 2008; 271(1-2):
97-103.
4) Belmin J, Expert Panel and Organisation Committee. Practical guidelines for the diagnosis and management of weight loss in Alzheimer’s disease:a consensus from appropriateness ratings of a large expert panel. J Nutr Health Aging. 2007; 11(1): 33-37.
5) Goldberg LS, Altman KW. e­ role of gastrostomy tube placement in advanced dementia with dysphagia: a critical review. Clin Interv Aging. 2014;
9: 1733-1739.
6) Affoo RH, Foley N, Rosenbek J, et al. Swallowing dysfunction and autonomic nervous system dysfunction in Alzheimer’s disease: a scoping reviewof the evidence. J Am Geriatr Soc. 2013; 61(12): 2203-2213.

▪ Search formula
PubMed search: June 8, 2015 (Monday)#1 (“Dementia” [Mesh] OR dementia) AND (“Deglutition Disorders/therapy” [Mesh] OR (dysphagia AND (therapy OR therapeutic OR
treatment))) AND (“percutaneous endoscopic gastrostomy” OR PEG OR (“Endoscopy” [Mesh] AND “Gastrostomy” [Mesh] AND “percutaneous”)
OR “Enteral Nutrition” [Mesh] OR “tube feeding”)
Ichushi search: June 8, 2015 (Monday)#1 (Dementia/TH or Dementia/TI) AND (Eating dysfunction/TH or Eating disorder/TI) AND (Gastrostomy construction/TH OR PEG/TI OR
Gastrostomy/TH OR Gastrostomy/TI OR Enteral nutrition/TH or Tube feeding/TI)

Chapter 3

63

CQ 3C-5

What are the interventions for sarcopenia and frailty?
AnswerDementia tend to coexist with sarcopenia and frailty. Resistance training may be useful in improving sarcopenia andfrailty associated with dementia.
C

Comments and evidence
Sarcopenia is a common pathological condition seen in old age. Sarcopenia is defined as “a syndrome characterized byprogressive and generalized loss of skeletal muscle mass and strength with a risk of adverse outcomes such as physicaldisability, poor quality of life and death” 1). The causes of sarcopenia include aging, reduced activity, poor nutrition, anddisease 1). Frailty is the decline of various physiological functions with ageing, and is a risk factor that leads to undesirable
outcomes such as falls, hospitalization, and death.
Sarcopenia and frailty tend to occur more frequently in older people with dementia than in older adults with normal
cognitive function. In recent years, the relationship between frailty and cognitive impairment has attracted attention 2).
Persons with Alzheimer’s disease in a nursing home who received the dual-task intervention of walking and conversation
showed less decline in physical function compared with persons given either conversation or walking intervention alone 3).
When frail persons with Alzheimer’s disease living at home participated in a home-based exercise program (aerobics, strength
training, and balance exercise) guided by the caregiver for 12 weeks, their hand function and lower extremity strength
significantly improved compared with the control group 4). A three-month resistance training program designed specifically for
older dementia persons significantly improved muscle strength and physical function compared with the control group 5). A
cohort study of frail older adults with dementia also found that 4 weeks of resistance exercise improved muscle strength andphysical functions 6). The above evidence shows that sarcopenia and frailty may be improved in people with dementia throughexercise customized for each individual.
Although there is no interventional study of nutrition therapy focused on people with dementia, nutritional supplementation
for sarcopenia generally improves muscle mass and muscle strength of older people 7). Hence, together with exercise,nutritional supplementation is important.

▪ References
1) Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on de­finition and diagnosis: Report of the European Working Groupon Sarcopenia in Older People. Age Ageing. 2010; 39(4): 412-423.
2) Halil M, Cemal Kizilarslanoglu M, Emin Kuyumcu M, et al. Cognitive aspects of frailty: mechanisms behind the link between frailty and cognitive
impairment. J Nutr Health Aging. 2015; 19(3): 276-283.
3) Tappen RM, Roach KE, Applegate EB, et al. Eff­ect of combined walking and conversation intervention on functional mobility of nursing homeresidents with Alzheimer disease. Alzheimer Dis Assoc Disord. 2000; 14(4): 196-201.
4) Steinberg M, Leoutsakos JM, Podewils LJ, et al. Evaluation of a home-based exercise program in the treatment of Alzheimer’s disease: the Maximizing
Independence in Dementia (MIND) study. Int J Geriatr Psychiatry. 2009; 24(7): 680-685.
5) Hauer K, Schwenk M, Zieschang T, et al. Physical training improves motor performance in people with dementia: a randomized controlled trial. J
Am Geriatr Soc. 2012; 60(1): 8-15.
6) Cadore EL, Moneo AB, Mensat MM, et al. Positive e­ffects of resistance training in frailty elderly patients with dementia after long-term physicalrestraint. Age (Dordr). 2014; 36(2): 801-811.
7) Malafarina V, Uriz-Otano F, Iniesta R, et al. E­ffectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: asystematic review. J Am Med Dir Assoc. 2013; 14(1): 10-17.

▪ Search formula
PubMed search: June 8, 2015 (Monday)#1 (“Dementia” [Mesh] OR dementia) AND (“Sarcopenia/therapy” [Mesh] OR(sarcopenia AND “Muscular Atrophy” [Mesh]) OR (sarcopenia
AND (therapy OR therapeutic OR treatment)) OR (frailty AND (therapy OR therapeutic OR treatment)))
Ichushi search: June 8, 2015 (Monday)#1 (Dementia/TH OR Dementia/TI) AND (sarcopenia/TI OR Sarcopenia/TH OR frailty/AL)

64

Clinical Practice Guideline for Dementia 2017

CQ 3C-6

What are the interventions and preventive measures for falls and fractures?
AnswerPeople with dementia have approximately 8 times higher risk for falls and approximately 3 times higher risk for fracturecompared with people without dementia. To prevent falls, use multi-faceted interventions including treatment ofunderlying diseases, adjustment of drugs, exercise, walking and balance training, training wearing aids, environmental
modification, and training to adjust to home environment. Also consider treatment for osteoporosis.
B

Comment and evidence
In older people, fracture caused by falling is one of the main causes of confining to bed, and falls lower the ability ofactivities of daily living (ADL) and motivation, and also induce delirium.
People with dementia have approximately 8 times higher risk for falls and approximately 3 times higher risk for fracturescompared with people without dementia 1). Dementia patients with orthostatic hypotension have a higher frequency of falls
compared to patients without orthostatic hypotension, with a hazard ratio of 2.13. For the incidence of falls, Parkinson’s
disease with dementia (PDD) was the highest, followed by dementia with Lewy bodies (DLB), vascular dementia, andAlzheimer’s disease (AD). For PDD and DLB, the high incidence may be related to orthostatic hypotension and autonomic
nervous system dysfunction 1).
A retrospective study conducted from 1988 to 2007 in the UK showed that the incidence of hip fracture was 17.4 per
1,000 people with dementia and 6.6 per 1,000 people without dementia, and the risk was 3.2 times higher in patients withdementia 2).
The guidelines for fall prevention prepared by the Orthopedic Surgery Committee of American Geriatric Society/ British
Geriatric Society3) recommends multifactorial interventions including minimization of medications, customized exercise
program, treatment of vision impairment, management of orthostatic hypotension, management of arrhythmia, vitamin D
supplementation, management of foot and footwear problems, modification of the home environment, and providing
education and information. However, there is insufficient evidence for supporting any single or multifactorial intervention
to reduce fall risk in older people with cognitive impairment. Subsequently, a meta-analysis of exercise interventions (7randomized controlled trials) was conducted, and found that exercise interventions reduce falls in people with dementia(odds ratio, 0.68) 4).
Although people with dementia are prone to osteoporosis-derived fractures, they are often not treated with drugs forosteoporosis. Consider appropriate assessment, treatment and guidance for osteoporosis 5). The risk of femoral neck fracture
is increased in older patients with Alzheimer’s disease who have vitamin K and vitamin D deficiency 6).

▪ References
1) Allan LM, Ballard CG, Rowan EN, et al. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One. 2009; 4(5):e5521.
2) Baker NL, Cook MN, Arrighi HM, et al. Hip fracture risk and subsequent mortality among Alzheimer’s disease patients in the United Kingdom,
1988-2007. Age Ageing. 2011; 40(1): 49-54.
3) Panel on Prevention of Falls in Older Persons, American Geriatrics Society and British Geriatrics Society. Summary of the Updated American
Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J Am Geriatr Soc. 2011; 59(1): 148157.
4) Chan WC, Yeung JW, Wong CS, et al. E­fficacy of physical exercise in preventing falls in older adults with cognitive impairment: a systematic review
and meta-analysis. J Am Med Dir Assoc. 2015; 16(2): 149-154.
5) Haasum Y, Fastbom J, Fratiglioni L, et al. Undertreatment of osteoporosis in persons with dementia? A population-based study. Osteoporos Int.
2012; 23(3): 1061-1068.
6) Sato Y, Honda Y, Umeno K, et al. The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly
patients with Alzheimer disease: a randomized controlled trial. Kurume Med J. 2011; 57(4): 117-124.

Chapter 3

65▪ Search formula
PubMed search: June 9, 2015 (Tuesday)#1 (“Dementia” [Mesh] OR dementia) AND (“Accidental Falls/prevention and control” [Mesh] OR (accident* AND (falls OR fall) AND (prevention
OR preventing)))
Ichushi search: June 9, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI) AND (Falls/TI OR Falls/TH) AND (Accident prevention/TH OR (SH = Prevention) OR Prevention/TI OR
Prevention/TI)

66

Clinical Practice Guideline for Dementia 2017

CQ 3C-7

What are the interventions for pressure ulcers?
AnswerCurrently, there is no clear evidence for the therapeutic or preventive effects of supplements, tube feeding, and parenteralnutrition for pressure ulcers, and there is a lack of high-level evidence for comprehensive management. For local treatment,
refer to the “Evidence-based Guidelines for Local Treatment of Pressure Ulcers” published by the Japanese Society ofPressure Ulcers.
2C

Comment and evidence
Pressure ulcers are necrosis of ischemic cutaneous or subcutaneous tissues caused by blood circulation failure due tocontinuous pressure on localized skin area. Pressure sores are formed frequently in sites with bone protrusion and little
subcutaneous fat tissue, and are strongly affected by ageing, undernutrition, motor paralysis, joint contracture, and urinary
and fecal incontinence. Pressure ulcers tend to occur when activities of daily living (ADL) decrease accompanying progressionof dementia.
Although it has been reported that an increase in number of pressure ulcers is related to higher risk of death in people withadvanced dementia 1), there is currently no clear evidence for the therapeutic or preventive effects of supplements, tube
feeding, and parenteral nutrition for pressure ulcers 2).
A meta-analysis has indicated that the presence of increasing pain is more useful than purulent exudate, heat, and redness
for the diagnosis of pressure ulcer infection 3).

▪ References
1) Cintra MT, de Rezende NA, de Moraes EN, et al. A comparison of survival, pneumonia, and hospitalization in patients with advanced dementia
and dysphagia receiving either oral or enteral nutrition. J Nutr Health Aging. 2014; 18(10): 894-899.
2) Langer G, Fink A. Nutritional interventions for preventing and treating pressure ulcers. Cochrane Database Syst Rev. 2014; (6): CD003216.
3) Reddy M, Gill SS, Wu W, et al. Does this patient have an infection of a chronic wound? JAMA. 2012; 307(6): 605-611.

▪ Search formula
PubMed search: June 9, 2015 (Tuesday)#1 (“Dementia” [Mesh] OR dementia) AND (“Pressure Ulcer” [Mesh] OR “bed sore” OR bedsore OR “decubitus position” OR “decubitus ulcer”
OR “pressure sore” OR “pressure ulcer”)
Ichushi search: June 9, 2015 (Tuesday)#1 (Dementia/TH OR Dementia/TI) AND (Pressure ulcer/TI OR decubitus ulcer/TH)

Chapter 3

67

CQ 3C-8

What are the approaches to treat acute physical illness?
AnswerIn people with dementia, acute physical illness is difficult to detect because typical symptoms are frequently absent andthe patients cannot complain. In Alzheimer’s disease, as dementia becomes severe, the number of hospital admissions
increases and mortality also increases.
C

Comment and evidence

There is still no evidence for acute physical illness in people with dementia.
According to the 2014 data of the Fire and Disaster Management Agency of Japan 1), 61.6% (2.03 million) of the patientstransported to emergency department were elderly, which doubled the percentage of 28.8% in 1993. Among these cases,
cerebrovascular system, heart disease, and respiratory system accounted for 11% each. For people with dementia transported
to emergency department, the major causes are pneumonia, stroke, fractures of lower limbs, bruise or sprain, ileus, andgastrointestinal bleeding 2, 3). In addition, more than 70% of 107 cases of suffocation are secondary to neurological disorders
including dementia, cerebral infarction, schizophrenia, and Parkinson’s disease 4). Therefore, neurological disorders including
dementia can be considered to be risk factor of suffocation. People with Alzheimer’s disease have more hospital admissions
than the general elderly population, and people with severe Alzheimer’s disease are hospitalized 2.3 times more than thegeneral elderly population 5). Moreover, people with dementia who require emergency admission have high death rate 6).
When a person with dementia is admitted to the hospital, make sure that the patient is placed in a room that is withinwatching distance from the nurses, and avoid rooms near the entrance and exit of the ward. Ensure safety by using measures
such as a bed exit sensor and a protective cover to prevent needle removal. Provide care with consideration to monitorchanges in patient’s symptoms or conditions. People with dementia are prone to develop delirium due to anxiety and fear asa result of change in environment and physical distress. As a measure for delirium, provide care with special considerations
for patients with dementia: ask family members to accompany the patient, have the same nurse in charge of the patient,explain the nurse call and location of the toilet in simple language, tell patient the status repeatedly, resolve pain / anxiety /insomnia, and do not restrain actions. Consider medication as necessary.
When dementia is advanced, detection of urinary tract infection is difficult because typical symptoms are frequently
absent, and the patients cannot complain7).

▪ References

1) Homepage of Fire and Disaster Management Agency. Status of emergency actions. 
http://www.fdma.go.jp/neuter/topics/­eldList9_3.html (In Japanese)2) Kimbara, Y, Yamada H, Kitagawa Y, et al. A survey of clinical characteristics of medical and psychiatric comorbidity patients at Emergency Medical
Center, Nagoya Ekisaikai Hospital. Journal of Japanese Society for Emergency Medicine (Nihon Rinsho Kyukyu Igaku Gakkaishi) 2014; 17(5):675-679. (In Japanese)3) Kubota Y, Kameda M, Tamura Y, et al. Emergency medical care for older adults with dementia at emergency center. Japanese Journal of Geriatric
Psychiatry (Ronen Seishin Igakushi) 2007; 18(1): 1204-1209. (In Japanese)4) Michiwaki Y, Aikoh K, Inoue M, et al. Clinical factors and medical cost of 107 cases of suffocation by food. Japanese Journal of Gerodontology(Ronen Shika Igaku) 2012; 26(4): 453-459. (In Japanese)5) Albert SM, Costa R, Merchant C, et al. Hospitalization and Alzheimer’s disease: Results from a community-based study. J Gerontol A Biol Sci Med
Sci. 1999; 54(5): M267-M271.
6) Sampson EL, Blanchard MR, Jones L, et al. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry.
2009; 195(1): 61-66.
7) D’Agata E, Loeb MB, Mitchell SL. Challenges in assessing nursing home residents with advanced dementia for suspected urinary tract infections.
J Am Geriatr Soc. 2013; 61(1); 62-66.

▪ Search formula

PubMed search: June 10, 2015 (Wednesday)#1 (“Dementia” [Mesh] OR dementia) AND (“Pneumonia/therapy” [Mesh] OR (pneumonia AND (therapy OR therapeutic OR treatment)) OR“Acute Disease/therapy” [Mesh] OR “Emergency Medicine” [Mesh])
Ichushi search: June 10, 2015 (Wednesday)#1 (Dementia/TH OR Dementia/TI) AND (Pneumonia/TH OR Pneumonia/TI OR Acute illness/TH OR Acute illness/TI OR Emergency
medicine/TH)

68

Clinical Practice Guideline for Dementia 2017

CQ 3C-9

How should decisions be made regarding invasive examinations and treatments
including dialysis and dental treatment?
AnswerWhen a person with dementia requires dialysis, refer to the “Proposal for the shared decision-making process regarding
initiation and continuation of maintenance hemodialysis” published by the Japanese Society for Dialysis Therapy. Dental
treatment and oral care are essential for people with dementia, and providing preventive and continuous oral hygiene
management is recommended.
D

Comments and evidence
As of the end of 2010, 9.9% of the total dialysis population had dementia (23,000 of 234,000 of all dialysis patients,
excluding those unknown and undocumented). For dialysis patients aged 90 years or above, 25-35% also have dementia andrequire support 1). As the number of people with dementia who require dialysis increase, there is also an increase in numberof patients who stand up or become restless during dialysis, impeding safe execution of dialysis. There are limits to sedationand caregiver attendance.
The “Proposal for the shared decision-making process regarding initiation and continuation of maintenance hemodialysis”
in Japan are recommendations on providing appropriate information to patients, giving support to patients when making
their own decisions, and obtaining written informed consent 2). Among the situations that require review of whether tosuspend dialysis, “extracorporeal circulation cannot be performed safely without restrain and sedation using medications”
and “oral intake not possible” and included, and these situations may arise in people with dementia.
As dementia emerges, self-cleaning behavior is impaired, and the state of oral hygiene worsens. People with dementia havemore caries and periodontal diseases than healthy people 4). Evidently oral care is important for the prevention of aspiration
pneumonia. In the clinical setting, patients with dementia often discontinue dental treatment because they do not understandthe meaning of the treatment. As a result, some patients require treatment under general anesthesia since the inflammation
cannot be controlled. Before dementia deteriorates to the above states, providing continuous preventive oral hygiene
management to people with dementia is recommended.

▪ References
1) Japanese Society for Dialysis Therapy. Data in Japan compiled by the Statistical Study Committee. http://docs.jsdt.or.jp/overview/index2011.html(In Japanese)
2) Watanabe Y, Hirakata H, Okada, et al. Proposal for the shared decision-making process regarding initiation and continuation of maintenancehemodialysis. Ther Apher Dial 2015; 19Suppl 1: 108-117.
3) Wu B, Plassman BL, Crout RJ, et al. Cognitive function and oral health among community-dwelling older adults. J Gerontol A Biol Sci Med Sci.
2008; 63(5): 495-500.

▪ Search formula
TraumaPubMed search: June 10, 2015 (Wednesday)#1 (“Dementia” [Mesh] OR dementia) AND (“Wounds and Injuries/therapy” [Mesh] OR ((fracture OR fractures OR trauma OR traumas) AND(therapy OR therapeutic OR treatment))
Ichushi search: June 10, 2015 (Wednesday)#1 (Dementia/MTH OR Dementia/TI) AND (Wound and injury/MTH OR Fracture/TI OR Trauma/TI)
Invasive examinations
PubMed search: June 12, 2015 (Friday)#1 (“Dementia/diagnosis” [Mesh] OR (dementia AND (diagnosis OR diagnostic))) AND (“Endoscopy” [Mesh] OR “Endoscopes” [Mesh] OR
endoscopy OR endoscopic OR endoscope* OR “invasive examination”)

Chapter 3

69

Ichushi search: June 12, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI) AND (Endoscopy/TH OR ((Endoscope/TH OR Endoscope/AL) AND (Diagnosis OR Examination)) OR(Invasive examination/AL NOT (Non-invasive examination /AL OR Non-invasive examination/AL)))
Surgery or dialysis
PubMed search: June 12, 2015 (Friday)#1 (“Dementia” [Mesh] OR dementia) AND (“surgical indication” OR operability OR “Renal Dialysis” [Mesh] OR dialysis OR hemodialysis OR
dialyses OR hemodialyses) OR “Dementia/complications” [Mesh] AND (“Surgical Procedures, Operative” [Majr] OR “surgery” [Subheading])
AND “Risk” [Mesh]
Ichushi search: June 12, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI) AND (Surgical indication/AL OR ((Surgery/MTH OR(SH = Surgical therapy) OR hemodialysis/TH OR
Dialysis/TI) AND Risk/TH))70

Clinical Practice Guideline for Dementia 2017

CQ 3C-10

What are the interventions for edema?
AnswerIn addition to interventions for immobility due to long-term bed confinement and undernutrition, provide treatments
for underlying diseases as well as for concomitant diseases such as skin infections and pressure ulcers. Pay attention to thepossibility of edema induced by drugs such as Yokukansan and antipsychotics, and consider discontinuation or dose
reduction of the causative drugs as appropriate.
C

Comments and evidence
Diseases that cause edema commonly seen in older people include: (1) causes of systemic edema; congestive heart failure,
renal disease, hepatic disease, and hypothyroidism, and (2) causes of localized edema; cerebrovascular disroder, deep veinthrombosis, knee osteoarthritis, and malignant tumors. Edema becomes more common with ageing, due to variability ofcapillary pressure, changes in interstitial components and reduced tissue pressure, lowered plasma osmotic pressure due todecreased serum albumin, and increased capillary permeability.
In people with dementia, it is necessary to consider the possibility of edema induced by drugs including antipsychotic
drugs 1) and Yokukansan 2), and to consider discontinuation or dose reduction of the causative drug as appropriate 2). According
to an observational study that examined the safety and efficacy of long-term use of Yokukansan in 163 patients who had beenprescribed Yokukansan for more than 6 months, edema appeared in 10.8% of the patients and many recovered by discontinuing
Yokukansan with no need for treatment 2).
Treatment of edema involves the treatment of underlying diseases identified by diagnosis of the cause as well as treatmentof coexisting illnesses such as skin infections and pressure ulcers. Especially in older people, extreme salt restriction andwater restriction to reduce edema may cause rapid intravascular dehydration, because of the low water and sodium retention
ability in older people. When using diuretics, monitor body weight to ensure that fluid is removed gradually. In addition,
since diuretics tend to disrupt electrolyte balance and cause hypotension, hypernatremia or hyponatremia, and hypokalemia,
close monitoring of blood electrolyte levels and urinary electrolyte excretion is necessary.

▪ References
1) Tan L, Tan L, Wang HF, et al. Efficacy and safety of atypical antipsychotic drug treatment for dementia: a systematic review and meta-analysis.
Alzheimers Res Ther. 2015; 7(1): 20.
2) Okahara K, Ishida Y. Safety and efficacy evaluation of long-term treatment with a traditional Japanese medicine, Yokukansan, on behavioral andpsychological symptoms of dementia. Dementia Japan. 2012; 26: 196-205. (In Japanese)▪ Search formula
PubMed search: June 12, 2015 (Friday)#1 (“Dementia” [Mesh] OR dementia) AND (“Edema” [Mesh] OR edema)
Ichushi search: June 12, 2015 (Friday)#1 (Dementia/TH OR Dementia/TI) AND (Edema/AL OR Edema/TH)

Chapter 3

71

CQ 3C-11

What are the interventions for urinary disorder?
AnswerMany people with dementia have functional urinary incontinence and urge urinary incontinence. Behavioral therapy
can be expected to be effective for urinary disorder, after ruling out underlying urological disorder. On the other hand,
there is no sufficient evidence for pharmacotherapy in people with dementia.
C

Comments and evidence
Carefully investigate the presence or absence of organic diseases causing urinary disorder, and rule out a diagnosis of suchdiseases. In people with dementia, functional urinary incontinence and urge urinary incontinence are common. Treat these
conditions by referring to guidelines (https://minds.jcqhc.or.jp/) 1-3).

1. Behavioral therapy 4-6)
The following interventions are recommended: (1) toileting assistance: [1] toileting at fixed time, [2] toileting according toan established voiding pattern, and [3] reeducating toileting habit; (2) bladder training; and (3) pelvic floor muscle
rehabilitation for stress urinary incontinence.

2. Pharmacotherapy for urinary disorder
For urge urinary incontinence in women, use anticholinergic drugs (propiverine and tolterodine). For prostatic hypertrophy
in overflow urinary incontinence, use the sympathetic selective α1 inhibitors (tamsulosin and naftopidil). For neurogenic
bladder, use cholinergic agonists (muscarinic receptor agonists; bethanechol). Attention should be paid to aggravation of
constipation and cognitive decline caused by anticholinergic drugs 7), and orthostatic hypotension caused by α1 inhibitors.
For overactive bladder with major symptoms of urinary urgency, urge incontinence, and frequent urination, use selective
muscarinic receptor antagonists (anticholinergic drugs) including fesoterodine, tolterodine, solifenacin, imidafenacin, andoxybutynin; and the β3 receptor agonist mirabegron 3). Oxybutynin is highly fat-soluble and crosses the blood-brain barrier,and the possibility of this drug of causing cognitive impairment has been suggested 8). In addition, combined use ofcholinesterase inhibitor and anti-cholinergic drug causes significant decline in activities of daily living compared withcholinesterase inhibitor monotherapy 9).

3. Other treatment methods1)
The following interventions have been recommended: (1) modify the environment depending on cognitive function andphysical function; (2) modify clothes; (3) use urinary catheter, suprapubic catheter, external urine receptacle, or urine
absorbent product; (4) use of bladder support device has been proposed; and (5) if urinary incontinence is detected, wipe thegenital area promptly to maintain cleanliness.

4. Drug-induced urinary disorder
Tricyclic antidepressants should be avoided as much as possible in male patients with urinary disorder 10). Among the
drugs for Parkinson’s disease, levodopa is recommended, whereas trihexyphenidyl and biperiden may cause urinary disorder.

▪ References
1) The Japanese Continence Society, Working Committee for Clinical Practice Guideline for Male Lower Urinary Tract Symptoms. Clinical Practice
Guideline for Male Lower Urinary Tract Symptoms. Tokyo: Blackwell Publishing; 2008. (In Japanese)
2) The Japanese Continence Society, Working Committee for Clinical Practice Guideline for Female Lower Urinary Tract Symptoms. Clinical Practice
Guideline for Female Lower Urinary Tract Symptoms. Tokyo: Blackwell Publishing; 2008. (In Japanese)3) The Japanese Continence Society, Working Committee for Guideline for Overreactive Bladder. Clinical Practice Guideline for Overreactive
Bladder. Tokyo: RichHill Medical Inc.; 2015. (In Japanese)4) Drennan VM, Greenwood N, Cole L, et al. Conservative interventions for incontinence in people with dementia or cognitive impairment, living at
home: a systematic review. BMC Geriatr. 2012; 12: 77.
5) Goode PS, Burgio KL, Richter HE, et al. Incontinence in older women. JAMA. 2010; 303(21): 2172-2181.
6) Hagglund D. A systematic literature review of incontinence care for persons with dementia: the research evidence. J Clin Nurs. 2010; 19(3-4): 303-312.

72

Clinical Practice Guideline for Dementia 2017

7) Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern
Med. 2015; 175: 401-407.
8) Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladderadequately measure central nervous system adverse events? J Am Geriatr Soc. 2011; 59(7): 13321339.
9) Sink KM, Th­ omas J 3rd, Xu H, et al. Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive
outcomes. J Am Geriatr Soc. 2008; 56(5): 847-853.
10) Thompson S, Herrmann N, Rapoport MJ, et al. Efficacy and safety of antidepressants for treatment of depression in Alzheimer’s disease: ametaanalysis. Can J Psychiatry. 2007; 52(4): 248-255.

▪ Search formula
PubMed search: June 12, 2015 (Friday), July 18, 2015 (Saturday)#1 (“Dementia” [Mesh] OR dementia OR alzheimer* [TI]) AND (“Urinary Incontinence/therapy” [Mesh] OR “Urinary disorders/therapy” [Mesh]
OR “Urinary Bladder Diseases/therapy” [Mesh] OR “Dysuria/therapy” [Mesh] OR ((“urinary incontinence” OR urinary disorder* [TI] OR urinary
incontinence* [TI] OR urinary bladder disease* [TI] OR bladder dysfunction* [TI] OR neurogenic bladder* [TI] OR dysuria [TI]) AND (therapy
OR therapeutic OR treatment OR management OR care OR training OR intervention)))Ichushi search: June 12, 2015 (Friday), July 18, 2015 (Saturday)#1 (Dementia/TH OR Dementia/TI) AND (urinary disorder/TH OR urinary disorder/TI OR Urinary incontinence/TI OR Bladder disease/TH
OR Bladder disease/TI OR Micturition pain/TH OR Micturition pain/TI OR Neurogenic bladder/TI OR Overactive bladder/TI)

Chapter 373

CQ 3C-12

What are the interventions for constipation?
AnswerConstipation is a common disease among people with dementia, and may impair quality of life (QOL) and causedelirium. Differentiate constipation from organic diseases, and use laxatives when diet (high fiber foods) and exercise do
not improve the constipation.
C

Comments and evidence
Constipation impairs QOL of people with dementia, causes irritability, decreases appetite, and may even result in delirium.
The rates of constipation by subtype of dementia are 43% in dementia with Parkinson’s disease, 28% in Lewy body disease,and 26% in vascular dementia, and were all higher than the rate of 2% in controls; whereas the rate is 3% in Alzheimer’s
disease and not significantly different from controls 1).
Constipation becomes more common with aging, due to weakness of the pelvic floor muscles, autonomic disturbances,
and abnormalities in the colon wall. Constipation is classified into functional (atonic, convulsive, rectal), organic,
symptomatic (such as diabetes and cerebrovascular disorder), and drug-induced. Atonic constipation is the most common,and is classified as functional constipation. Organic constipation is caused by colon cancer or scarring. Medications associatedwith constipation include anticholinergic drugs, antidepressants, antipsychotic drugs, antiparkinsonian drugs, antihistamines,
diuretics, and opioids 2). Symptoms of nausea/vomiting, abdominal distension, and retention of feces and gas suggest ileus.
Change in stool caliber, occult blood in stool, bloody stool, iron deficiency anemia, and weight loss are signs of suspectedorganic constipation 2).
After ruling out the above conditions, use non-pharmacological interventions such as lifestyle modification and diettherapy. Recommend patients to (1) eat a fiber-rich diet, (2) keep regular eating and defecation habits, and (3) do walking
exercise. For convulsive constipation, it is important to remove stress. For atonic constipation, advice patients to drink
sufficient water to prevent hard stool, and to take water-soluble vitamins such as vitamins B1 and B2, as well as to increasebifidobacteria in the bowel. If there is no improvement despite the above interventions, prescribe pharmacotherapy. Laxatives
include osmotic laxatives (magnesium oxide), colonic stimulants (such as senna, sennoside, Daio, and sodium picosulfate),
chloride channel activator (lubiprostone) that promotes water secretion in the intestinal tract, Daikenchuto suppository, andenemas. Select medications according to the number of defecations and the nature of the stool.
Although enema is widely used, the rates of complications such as perforation, hyperphosphatemia, and sepsis are
particularly high in older patients, and should be used with caution 3).

▪ References
1) Allan L, McKeith I, Ballard C, et al. The prevalence of autonomic symptoms in dementia and their association with physical activity, activities ofdaily living and quality of life. Dement Geriatr Cogn Disord. 2006; 22: 230-233.
2) Lindberg G, Hamid SS, Malfertheiner P, et al. World Gastroenterology Organisation global guideline: Constipation- a global perspective. J Clin
Gastroenterol. 2011; 45(6): 483-487.
3) Niv G, Grinberg T, Dickman R, et al. Perforation and mortality after cleansing enema for acute constipation are not rare but are preventable. Int J
Gen Med. 2013; 6: 323-328.

▪ Search formula
PubMed search: June 12, 2015 (Friday), July 18, 2015 (Saturday)#1 (“Dementia” [Mesh] OR dementia OR alzheimer* [TI]) AND (“Constipation/therapy” [Mesh] OR “Colonic Diseases, Functional/therapy”[Mesh] OR ((constipation [TI] OR bowel dysfunction* [TI] OR colonic disease* [TI] OR neurogenic bowel*[TI]) AND (therapy OR therapeutic
OR treatment OR management OR care OR training OR intervention)))Ichushi search: June 12, 2015 (Friday), July 18, 2015 (Saturday)#1 (Dementia/TH OR Dementia/TI) AND (Constipation/TH OR Constipation/TI OR Defecation disorder/TH OR Defecation disorder/TI OR
Colonic disease-functional/ TH OR Functional colonic disease/TI OR Neurogenic bowel/TI OR irritable colon/TI)

74

Clinical Practice Guideline for Dementia 2017

CQ 3C-13

How should diabetes, hypertension and other lifestyle-related diseases
be managed?
Recommendation
Individualized approach to diabetes control is recommended, with consideration of the severity of dementia andphysical dysfunction, coexisting diseases, frailty, and other factors. Although there is little evidence regarding the effects
of antihypertensive treatment for hypertensive patients with dementia, treatment that does not excessively reduce bloodpressure should be considered.
2C

Comments and evidence

It has been pointed out that lifestyle-related diseases (or vascular risk factors) such as hypertension, diabetes, dyslipidemia,
and obesity that coexist with dementia may potentially modify the progression of cognitive dysfunction. Proper treatmentof vascular risk factors accompanying Alzheimer’s disease dementia has been shown to mitigate the deterioration of Mini
Mental State Examination (MMSE) score 1).
For glycemic control in older diabetic patients who have developed dementia, set the treatment target ​considering theactivities of daily living (ADL), coexisting diseases, and risk of severe hypoglycemia. Hypoglycemia, falls and fractures
increase when HbA1c is less than 7.0%; and cognitive decline, frailty, and geriatric syndrome increase gradually when
HbA1c exceeds 8.0%. In older people with diabetes, setting HbA1c target for individual patient is recommended, taking
into consideration not only the presence or absence and severity of dementia, but also the coexisting diseases, basic ADL(BADL) and instrumental ADL (IADL), frailty, and risk of severe hypoglycemia 2). Current recommendation is HbA1c 7.0%
to below 7.5% for older people with normal cognitive and physical functions, below 8.0% for mild to moderate dementia,
and below 8.5% for moderate to severe dementia or severely impaired physical function. Furthermore, according to the
proposal of the Joint Committee in Japan, lower limits of the targets have been set to avoid hypoglycemia in patients using
drugs for which severe hypoglycemia is a concern (such as insulin, sulphonylureas, and glinides).
There is little evidence for the effect of antihypertensive agents in hypertensive patients with dementia. An observational
study finds that antihypertensive therapy prevents the progression of mild cognitive impairment to Alzheimer’s disease
dementia 3). Antihypertensive treatment should be considered 4). However, although there are no descriptions for therecommended blood pressure targets for older people with frailty or dementia, care should be taken not to excessively lower
blood pressure in older people with dementia receiving antihypertensive treatment 5).

▪ References
1) Deschaintre Y, Richard F, Leys D, et al. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology. 2009;73(9): 674-680.
2) The Japan Diabetes Society / Japan Geriatrics Society Joint Committee on Improving Care for Elderly Patients with Diabetes. Glycemic targets for
elderly patients with diabetes. 2016. (In Japanese)
3) Li J, Wang YJ, Zhang M, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology. 2011;76(17): 1485-1491.
4) Japan Society for Hypertension Committee for Guidelines for the Management of Hypertension. Guidelines for the Management of Hypertension
2014 (JSH 2014). Tokyo: LifeScience Shuppan; 2014. (In Japanese)5) Mossello E, Pieraccioli M, Nesti N, et al. E­ffects of low blood pressure in cognitively impaired elderly patients treated with antihypertensive drugs.
JAMA Intern Med. 2015; 175(4): 578-585.

▪ Search formula

PubMed search: July 3, 2015 (Friday)#1 (“Dementia/prevention and control” [Majr] OR (dementia [TI] AND (prevent* OR control*)) OR “Cognition Disorders/prevention and control” [Majr]
OR ((cognition disorder* [TI] OR “cognitive dysfunction” [TI]) AND (prevent* OR control*))) AND (“Diabetes Mellitus” [Mesh] OR “Hypertension”[Mesh] OR ((“diabetes mellitus” [TI] OR hypertension [TI])) OR “Life Style” [Majr] OR lifestyle related disease* [TI] OR lifestyle disease* [TI])
Ichushi search: July 3, 2015 (Friday)#1 (Dementia/MTH OR Dementia/TI OR Cognitive impairment/MTH OR Cognitive impairment/TI) AND ((SH = Therapeutic use, treatment,
drug treatment, surgical treatment, transplantation, dietary treatment, psychiatric treatment, radiotherapy, rehabilitation, prevention)OR
Pharmacotherapy/TH OR Pharmacological effect/TH OR Treatment/TI OR Therapy/TI OR Control/TI OR Prevention/TI) AND (Lifestyle
related disease /TH OR Lifestyle related disease /TI OR Diabetes/TH OR Diabetes/ TI OR Hypertension/TH OR Hypertension/TI)

Chapter 375